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ABSTRACT 
Author: Polanka, Brittanny M. MS 
Institution: Purdue University 
Degree Received: December 2017 
Title: Is Insomnia an Independent Predictor of Incident Atherosclerotic Cardiovascular 
Disease Among HIV-Infected Veterans? 
Major Professor: Jesse C. Stewart 
 
While insomnia/sleep disturbance has been identified as an independent predictor of 
cardiovascular disease in the general population, no studies have examined whether 
insomnia contributes to the elevated cardiovascular disease (CVD) risk in people with 
human immunodeficiency virus (HIV). Thus, the current study examined whether 
insomnia symptoms predict incident atherosclerotic CVD in the Veterans Aging Cohort 
Study 9 (VACS9), a prospective cohort of HIV-infected (n = 3,138) and uninfected (n = 
3,010) Veterans utilizing self-report measures and administrative data. In partial support 
of my hypotheses, I found that HIV-infected Veterans bothered a lot by difficulty falling 
or staying asleep have greater CVD risk than HIV-infected Veterans without these 
symptoms. This study failed to replicate previous findings that insomnia symptoms are 
predictive of incident CVD in uninfected adults, which may be due to issues related to the 
validity of the insomnia symptoms assessment. A number of methodological issues are 
identified and considered in the interpretation of the current study results. Given the 
novelty of examining insomnia as a predictor of incident CVD in HIV-infected adults and 
the limitations of the present study, future research is needed to better elucidate the 
association between insomnia and future CVD in this population.
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CHAPTER 1. INTRODUCTION 
The American Heart Association’s 2015 update of heart disease and stroke statistics 
indicates that cardiovascular disease (CVD) remains the leading cause of death of men and 
women in the U.S. (Mozaffarian et al., 2015). In the general population, psychosocial 
factors, including insomnia, have been identified as predictors of CVD onset above and 
beyond the risk attributable to traditional CVD risk factors. Of relevance to the present 
study, adults infected with the human immunodeficiency virus (HIV) are more likely to 
report insomnia symptoms and develop CVD than adults from the general population. To 
date, however, no studies have examined whether insomnia is a risk factor for CVD in the 
HIV-infected population. The present study seeks to address this important gap in 
knowledge. 
 In this thesis, I present several topics before discussing the present study's 
methodology. First, I review research examining insomnia, CVD, and the insomnia-CVD 
relationship in the general population. Second, I review the same literatures in the HIV-
infected population. Third, I present the rationale for and hypotheses of the present study. 
Fourth, I review the results of the present study. Lastly, I discuss limitations and 
interpretive issues, fit with literature, directions for future research, and final conclusions 
of the present study. 
Insomnia 
Epidemiology. Insomnia, as a symptom and a disorder, has only recently been 
recognized as an independent concern from other mental and physical conditions. This shift 
in attention is reflected in the ICSD-3’s (International Classification of Sleep Disorders-3; 
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American Academy of Sleep Medicine, 2014) and the DSM-5’s (Diagnostic and Statistical 
Manual of Mental Disorders-5; American Psychiatric Association, 2013) acknowledgment 
of insomnia as a disorder irrespective of its manifestation as either a primary disorder or a 
disorder secondary to a mental or physical comorbidity (Morin & Jarrin, 2013). Insomnia 
symptoms include: (1) a subjective complaint of poor sleep quantity or quality (e.g., 
difficulty initiating, maintaining, or returning to sleep), (2) significant distress or 
impairment in functioning, and (3) the presence of insomnia symptoms for at least three 
nights per week for at least 3 months (American Academy of Sleep Medicine, 2014; 
American Psychiatric Association, 2013). 
The prevalence and incidence rates of insomnia vary widely depending upon the 
study design, sample, and follow-up length. Prevalence rates of insomnia symptoms (i.e., 
sleep disturbance) range from 5-50% (Ohayon, 2002). However, when using criteria set by 
either the ICSD or DSM (i.e., insomnia diagnosis), the prevalence rate range is a more 
conservative 6-10% (Jansson-Frojmark & Linton, 2008; Morin, LeBlanc, Bélanger, Ivers, 
& Mérette, 2011; Morin, LeBlanc, Daley, Gregoire, & Merette, 2006; Ohayon & Reynolds, 
2009; Roth et al., 2006). A prospective population-based study in Canada estimated the 1-
year incidence of insomnia to be 7.3%. This estimate dropped to 3.9% when limited to 
those without a lifetime history of insomnia episodes (LeBlanc et al., 2009). 
There is mixed evidence regarding racial/ethnic differences in insomnia. One study 
reported that the prevalence of insomnia disorder did not differ between Caucasian and 
African American adults (Kalmbach, Pillai, Arnedt, & Drake, 2016). Although few 
investigations have focused on insomnia disorder, many studies have examined 
racial/ethnic differences in insomnia symptoms and sleep duration. A 2010 meta-analysis 
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found that Caucasians report higher rates of insomnia symptoms than African Americans 
(Ruiter, DeCoster, Jacobs, & Lichstein, 2010). This conflicts with studies that have since 
observed either no difference in insomnia symptoms between Caucasian, African 
American, and Hispanic adults (Baldwin et al., 2010) or a higher rate of poor sleep quality 
in African Americans than in Caucasians (Chen et al., 2015). Similarly, there does not 
appear to be a difference in insomnia symptoms between Caucasian or Hispanic Americans 
(Baldwin et al., 2010). Evidence also suggests a consistent pattern of shorter sleep duration 
in African Americans than in Caucasians (Chen et al., 2015; Ruiter, DeCoster, Jacobs, & 
Lichstein, 2011), an association that may be mediated by socioeconomic factors 
(Stamatakis, Kaplan, & Roberts, 2007). 
Research supports sex differences in insomnia. In a large community-based sample 
of U.S. adults, it was found that women comprise the majority of adults with current 
insomnia disorder and normal sleep duration (12% vs. 6%) and with current insomnia 
disorder and short sleep duration (12% vs. 8%; Kalmbach et al., 2016). Concerning 
insomnia symptoms, a meta-analysis reported that women were 41% more likely than men 
to report insomnia symptoms and that this sex difference exists in young, middle, and late 
adulthood, with the greatest sex difference observed among the elderly (Zhang & Wing, 
2006). Others have found that elderly women were more likely than elderly men to report 
difficulty initiating sleep and early morning awakening (Jaussent et al., 2011). Thus, it 
appears that women are more prone than men to experiencing both insomnia disorder and 
symptoms. 
There are mixed results regarding age differences in insomnia. Several studies have 
reported that older adults have a higher prevalence of insomnia symptoms than younger 
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adults (Leger, Guilleminault, Dreyfus, Delahaye, & Paillard, 2000; Sivertsen, Krokstad, 
Øverland, & Mykletun, 2009; Terzano et al., 2004). However, there is debate regarding 
whether this relationship can be explained by other conditions common among older adults 
that disrupt sleep (e.g., chronic pain, dementia, and other medical comorbidities; Foley, 
Ancoli-Israel, Britz, & Walsh, 2004; Taylor et al., 2007; Tractenberg, Singer, & Kaye, 
2005) or by changes in sleep architecture with aging (e.g., phase advance of normal 
circadian rhythm, reduced total sleep time, and reduced delta sleep; Wolkove, Elkholy, 
Baltzan, & Palayew, 2007). 
Pathophysiology. Although there is no universally accepted model of insomnia, a 
common conceptualization is the 3P stress-diathesis model. This model proposes three 
levels of factors thought to cause and maintain insomnia: (1) predisposing factors, (2) 
precipitating factors, and (3) perpetuating factors (Spielman, Caruso, & Glovinsky, 1987). 
Predisposing factors are biopsychosocial characteristics predisposing an individual to the 
development of insomnia, such as genetic factors, trait sleep reactivity, and cognitive 
intrusions (Drake, Pillai, & Roth, 2014; LeBlanc et al., 2009; Vgontzas et al., 2001). 
Precipitating factors are usually acute events that interact with predisposing factors, 
resulting in a transient insomnia episode. Examples of precipitating factors are stressful 
life events, medical conditions, and psychiatric disorders (LeBlanc et al., 2009). 
Perpetuating factors include beliefs and compensatory behaviors adopted by the individual 
to cope with insomnia in the short-term, inadvertently perpetuating sleep disturbances and 
leading to chronic insomnia. For example, excessive time in bed, napping, deconditioning 
of the bedroom for sleep, and sleep worry are all factors that can perpetuate a disrupted 
sleep cycle (Espie, 2007; Stepanski & Wyatt, 2003). 
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In line with the National Institute of Mental Health’s “Research Domain Criteria” 
(RDoC), a more biologically comprehensive model has recently been proposed to 
complement the 3P model (Levenson, Kay, & Buysse, 2015). This model adds that 
insomnia is likely to develop in those with a genetic predisposition for atypical 
neurobiological processes, producing a trait disposition for insomnia (i.e., predisposing 
factor) that is then triggered by precipitating factors and continues as a result of biological 
and psychological processes (i.e., perpetuating factors). Identified candidate genes of 
insomnia include Apoɛ4, PER34/4, HLA DQB1 * 0602, homozygous Clock gene 3111C/C 
Clock, and the short (s-) allele of the 5-HTTLPR (Levenson et al., 2015; Palagini, Biber, 
& Riemann, 2014). It is proposed that these genetic factors produce a trait disposition for 
insomnia through atypical neurobiological processes, such as dysregulated wake-
promoting/sleep-suppressing and sleep-promoting/wake-suppressing substances (e.g., γ-
aminobutyric acid [GABA] and cortisol). Finally, chronic insomnia is thought to result 
from continuous dysregulation of these wake- and sleep-regulating substances and brain 
changes (e.g., increased high-frequency electroencephalogram [EEG] activity near sleep 
onset, increased sensory information processing, and EEG arousal during REM sleep; 
Levenson et al., 2015), as well as the psychological and behavioral perpetuating factors 
included in the 3P model.  
Cardiovascular Disease 
Epidemiology. CVD is an umbrella term capturing coronary artery disease (CAD), 
cerebrovascular disease, and peripheral arterial disease, among other conditions (World 
Health Organization, 2015). Atherosclerotic CVD, or CAD, is a disease affecting the major 
blood vessels of the heart. The present study will focus on acute myocardial infarction 
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(AMI), coronary revascularization, and stroke, which are clinical manifestations of 
atherosclerotic CVD. An AMI occurs as a result of prolonged ischemia (i.e., inadequate 
blood supply) to heart muscles, leading to cell death (Thygesen et al., 2012). Prolonged 
ischemia is primarily caused by two types of events: (1) a blood clot could become lodged 
in a coronary artery, blocking blood flow, or (2) an atherosclerotic plaque in a coronary 
artery could rupture, spilling its contents into the artery and blocking blood flow. Coronary 
revascularization is used to treat CAD and includes percutaneous coronary intervention 
(PCI) and coronary artery bypass grafting (CABG). PCI, also known as angioplasty, is a 
non-surgical intervention option for the widening of narrowed or blocked coronary arteries. 
This group of procedures involves threading a catheter through the coronary arteries to the 
narrowed blood vessel, inflating the balloon to widen the vessel and push any existing 
plaque or blood clot into the artery walls, and placing a stent into the newly widened blood 
vessel in order to keep the vessel from narrowing in the future (American Heart 
Association, 2017). CABG is a surgical intervention option for the bypassing of narrowed 
or blocked coronary arteries. This group of procedures involves harvesting a vein from 
another part of the body to be placed into the heart as a means of bypassing, or going 
around, the narrowed or blood vessels (American Heart Association, 2017). A stroke also 
occurs as a result of prolonged ischemia leading to cell death. Unlike ischemia leading to 
AMI, ischemia leading to stroke is localized in the blood vessels of the brain and leads to 
cell death of brain tissue. In stroke, prolonged ischemia is primarily caused by a blood clot 
or other debris becoming lodged in an artery that feeds the blood vessels of the brain 
(Moskowitz, Lo, & Iadecola, 2010). A small percentage of strokes are caused by 
hemorrhaging or a rupturing of the blood vessels in the brain. 
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CAD’s estimated prevalence is 6.2% in Americans over the age of 20 (7.6% in men 
and 5.0% in women), and AMI’s estimated prevalence is 2.8% (4.0% in men and 1.8% in 
women; Mozaffarian et al., 2015). The incidence of CAD increases with age and differs by 
sex (Mozaffarian et al., 2015). Specifically, first cardiac events for women are, on average, 
about 10 years later than those for men (Ferreira-Gonzalez, 2014). The delay in incidence 
of CAD between the sexes increases to 20 years for AMI only (Mozaffarian et al., 2015). 
Due to an increase in CVD primary prevention efforts over the last decade, there has been 
a shift in the prevalence of coronary revascularization procedures. One study examining 
the trends of PCI and CABG among Medicare patients between 2001 and 2009 found that, 
(1) while PCI use showed a mean annual increase of 1.3% per 1,000 Medicare beneficiaries 
during 2001-2009, this primarily occurred between 2001-2004 as PCI use showed a 
decrease of 5% during 2004-2009, and (2) CABG use showed a mean annual decreased of 
5% during 2001-2009 (Riley, Don, Powell, Maynard, & Dean, 2011). Stroke’s estimated 
prevalence is 2.6% in Americans over the age of 20 (Mozaffarian et al., 2015). The 
incidence of stroke increases with age, with men showing a higher incidence rate in 
younger and middle adulthood; this gender gap narrows in the oldest age groups, with the 
incidence of stroke in women becoming equal or higher than that of men (Mozaffarian et 
al., 2015). 
Pathophysiology. The underlying condition that causes CAD and stroke is 
atherosclerosis, which refers to the thickening and hardening of the artery walls due to the 
accumulation of lipids, leukocytes, calcium, and smooth muscle cells (Libby, 2006). The 
development of atherosclerosis occurs through two mechanisms acting simultaneously: (1) 
a traditional circulatory process and (2) an inflammatory process (Libby, 2003, 2006). The 
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traditional circulatory process is characterized by the accumulation of lipids in the 
endothelium, the single layer of cells that lines the blood vessels (Weber & Noels, 2011). 
Lipids trapped in the artery wall are then vulnerable to oxidative changes. Triggers of this 
process include a diet high in saturated fat, smoking, hypertension, obesity, and insulin 
resistance.  
Endothelial damage resulting from this circulatory process initiates the 
inflammatory process through the expression of adhesion cells (Libby, 2006). These 
adhesion cells bind with passing leukocytes (i.e., monocytes and T lymphocytes), which 
then enter the artery wall. Monocytes in the artery wall mature into macrophages tasked 
with ingesting foreign substances, including the accumulated lipids. As the macrophages 
work, they become packed with lipids and resemble foam and, thus, are named foam cells. 
T lymphocytes are also attracted to lipids in the artery wall. Together with the foam cells, 
they make up what is called the fatty streak. The macrophages and T lymphocytes multiply, 
amplifying the inflammatory response by releasing cytokines and growth factors. The 
smooth muscle cells of the artery also migrate to the surface of the fatty streak to replicate 
and form a fibrous cap in an attempt to heal the artery wall and protect the flow of blood. 
The lesion has now progressed to an atheromatous plaque. Once the fatty streak is sealed 
off, some foam cells die and release their lipids, which is why the core of the plaque has 
been termed the lipid or necrotic core.  
The interaction between circulatory and inflammatory processes can spiral into a 
vicious cycle, which can ultimately lead to thrombotic complications. A severe thrombotic 
complication of CAD is AMI (Thygesen et al., 2007). One way an AMI can occur is 
through excessive plaque build-up in a coronary artery that eventually blocks blood flow 
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to the heart muscle. However, the majority of AMIs (60-70%) are the result of plaque 
ruptures (Falk, Shah, & Fuster, 1995). When a plaque ruptures, the necrotic core is 
suddenly released into the blood stream. T lymphocytes released from the core then 
stimulate foam cells to produce high levels of tissue factor to form a blood clot and release 
chemicals to impede the body’s attempts to decompose the clot. The clot, in turn, blocks 
blood flow to the heart muscle, resulting in cell death. A severe complication of 
cerebrovascular disease, another form of CVD, is stroke. The majority of strokes occur as 
a result of a blood clot or debris that build up and block the blood flow in the brain 
(Moskowitz et al., 2010). Blood clots can originate in the brain or may travel from 
atherosclerotic plaques in the coronary arteries. A small portion (~15%) of strokes occur 
as a result of the rupturing of the artery wall (Moskowitz et al., 2010). 
Insomnia-Cardiovascular Disease Relationship 
Epidemiology. The literature examining insomnia as a risk factor of CAD has 
grown steadily over the past few decades. A meta-analysis of 10 studies published in 1999 
found a significant pooled odds ratio of 1.70 for the relationship between subjective sleep 
complaints and CAD events (Schwartz et al., 1999). A more recent meta-analysis of 13 
prospective cohort studies confirmed these results, as a significant pooled odds ratio of 
1.45 was found for the relationship between subjective sleep complaints and total CVD 
events (i.e., acute myocardial infarction, coronary artery disease, stroke, or death from any 
of these conditions; Sofi et al., 2014). Although the Sofi et al. (2014) meta-analysis did not 
include studies published after 2011, another meta-analysis published that same year did 
and examined the prospective associations between subjective sleep complaints/insomnia 
diagnosis and various types of CVD events (Li, Zhang, Hou, & Tang, 2014). Li and 
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colleagues (2014) found significant pooled relative risk ratios of 1.33 for CVD mortality 
(13 studies), 1.55 for stroke (2 studies), 1.28 for CAD (3 studies), and 1.41 for myocardial 
infarction (7 studies). Thus, accumulating evidence suggests that self-reported sleep 
disturbance may increase the risk of CVD events, including AMIs and strokes.  
To date, only one study has examined insomnia disorder as a predictor of CVD 
events. Hsu et al. (2015) prospectively examined the association between insomnia 
diagnoses (i.e., diagnostic codes in Taiwan’s National Health Insurance Research 
Database) and CVD outcomes among 44,080 Taiwanese adults and observed hazard ratios 
of 1.81 for total CVD events, 1.85 for stroke, and 1.68 for AMI after adjustment for age, 
sex, some traditional CVD risk factors, and select medical conditions. Thus, insomnia, 
operationalized as a clinical diagnosis in the medical record, may also be a risk factor for 
CVD events, including AMI. However, further studies are needed to examine if this 
association holds after accounting for other potential confounders, including race/ethnicity, 
socioeconomic status, and other CVD risk factors (i.e., smoking, body mass index, poor 
diet, physical inactivity, and family history of CVD).  
Related literature exists examining the prospective relationship between short sleep 
duration and incident CVD. Short sleep duration, typically defined as ≤ 6 hours of sleep 
per night, is related to the insomnia diagnostic criterion of subjective complaint of poor 
sleep quantity but does not include subjective perception of sleep quality or significant 
distress or impairment in functioning. A 2011 meta-analysis of 15 studies examining the 
prospective association between short sleep duration and incident CVD found significant 
pooled relative risk ratios of 1.48 for CAD and 1.15 for stroke, but no significant 
association was observed for total CVD (Cappuccio, Cooper, D'Elia, Strazzullo, & Miller, 
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2011). Most epidemiologic studies conducted since that meta-analysis also report 
significant associations between short sleep duration and incident CVD (Michal et al., 
2014; Rod et al., 2014; Sands-Lincoln et al., 2013; Westerlund et al., 2013). However, one 
recent epidemiology study found a significant association between short sleep duration and 
incident CVD only among participants classified as unhealthy (i.e., current/past cancer, 
stroke, or diabetes; Holliday, Magee, Kritharides, Banks, & Attia, 2013). 
Candidate mechanisms. Insomnia could lead to the development of CVD through 
both behavioral and biological pathways. Regarding behavioral candidate mechanisms, 
insomnia has been related to physical inactivity, excessive alcohol use (Haario, Rahkonen, 
Laaksonen, Lahelma, & Lallukka, 2013; Hoefelmann et al., 2012), smoking (Htoo, Talwar, 
Feinsilver, & Greenberg, 2004), and poor diet (Hoefelmann et al., 2012). Regarding 
biological candidate mediators, insomnia has been linked to hypothalamic-pituitary-
adrenal axis (Balbo, Leproult, & Van Cauter, 2010) and autonomic nervous system 
(Calandra-Buonaura, Provini, Guaraldi, Plazzi, & Cortelli, 2016) dysregulation, chronic 
inflammation (Irwin, Olmstead, & Carroll, 2015), altered coagulation (Jackowska & 
Steptoe, 2015), and endothelial dysfunction (Kohansieh & Makaryus, 2015). Additionally, 
insomnia has been associated with traditional CVD risk factors, such as obesity (Janson, 
Lindberg, Gislason, Elmasry, & Boman, 2001; Lyytikainen, Lallukka, Lahelma, & 
Rahkonen, 2011), hypertension (Fernandez-Mendoza et al., 2012; Vgontzas, Liao, Bixler, 
Chrousos, & Vela-Bueno, 2009), and diabetes (Hoefelmann et al., 2012; Vgontzas, 
Calhoun, et al., 2009), which have both behavioral and biological aspects. 
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Human Immunodeficiency Virus 
Epidemiology. It has been estimated that HIV, an infectious disease that is the 
precursor to acquired immunodeficiency syndrome (AIDS), affects 2.3 million people in 
high-income countries, which represents only 6.7% of the global total of people living with 
HIV (Sullivan, Jones, & Baral, 2014). HIV infection can be acquired through the sharing 
of bodily fluid (e.g., via a blood transfusion, needle sharing, or unprotected sex (Patel et 
al., 2014). The prevalence of HIV is increasing in nearly every country, largely due to 
averted HIV/AIDS-related deaths by antiretroviral therapy (ART; UNAIDS, 2013). While 
the HIV prevalence rate is on the rise, the incidence rate for ages 15 to 59 has decreased 
from 0.11% in 1996 to 0.05% in 2012 worldwide (UNAIDS, 2013). Current ART treatment 
guidelines recommend a combination of two nucleoside reverse transcriptase inhibitors 
(NRTI) plus a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor 
(NNRTI; Tseng, Seet, & Phillips, 2015). These regimens are typically referred to as either 
highly active antiretroviral therapy (HAART) or combination antiretroviral therapy 
(cART).  
Pathophysiology. Once the body is infected with HIV, the virus targets and kills a 
multitude of cells throughout the body. The infection targets CD4+ T cells throughout the 
body; monocytes and macrophages in the spleen, brain, liver, and lungs; and dendritic cells 
in germinal centers such as the vagina, tonsils, and rectum (Lucas & Nelson, 2015). Such 
extreme cell death leads to subsequent HIV-related disease in three main ways: (1) 
reduction of CD4+ T cells resulting in compromised immune function and increased risk 
of opportunistic infections, (2) mononuclear cell activation (e.g., monocytes, lymphocytes, 
and dendritic cells) resulting in direct tissue damage, and (3) endothelial cell dysfunction 
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and chronic immune activation resulting in indirect tissue damage. The use of ART 
suppresses the HIV-1 RNA viral load circulating in the blood and allows for the 
repopulation of CD4+ T cells (Tseng et al., 2015). However, the HIV-1 RNA viral load in 
the central nervous system (CNS) is not well controlled by ART (Dahl et al., 2014). 
Insomnia in HIV 
Epidemiology. Sleep disturbance and insomnia symptoms are highly prevalent in 
the HIV-infected population. The first qualitative review of sleep disturbance among HIV-
infected individuals examined 29 studies and identified sleep disturbance as a frequent 
complaint and present during all stages of HIV infection (Reid & Dwyer, 2005). A more 
recent qualitative review of 19 studies reported sleep disturbance prevalence estimates 
between 29-97% (Low, Goforth, Preud'homme, Edinger, & Krystal, 2014). This was 
followed by a meta-analysis reporting the prevalence of sleep disturbance to be 58% in an 
accumulated sample of 9,246 HIV-infected adults from 27 studies (Wu, Wu, Lu, Guo, & 
Li, 2015), much higher than the 36% reported in the general population (Roth et al., 2006). 
Despite evidence indicating that sleep disturbance is a prevalent problem among 
HIV-infected individuals, only one study has examined the prevalence of insomnia based 
on diagnostic criteria. Using a structured interview for sleep disorders, a small study of 29 
HIV-infected and 19 uninfected African Americans observed an insomnia disorder 
prevalence of 56% (Gamaldo et al., 2013). Thus, the prevalence of insomnia disorder is 
unknown in the HIV-infected population (Low et al., 2014).  
Pathophysiology. Evidence suggests that traditional insomnia risk factors or 
precipitating factors – e.g., stress, fatigue, substance use, depression, and anxiety (Allavena 
et al., 2016; Jabbari, Dabaghzadeh, Khalili, & Abbasian, 2015; Jean-Louis et al., 2012) – 
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are also operating in the HIV-infected population. In addition, HIV-specific insomnia risk 
factors have been identified and include duration HIV infection (Allavena et al., 2016), 
advanced disease stage, cognitive impairment (Rubinstein & Selwyn, 1998), and use of the 
NNRTI efavirenz (Allavena et al., 2016; Low et al., 2014). CD-4+ T cell count and HIV-1 
RNA viral load do not appear to be associated with insomnia risk (Low et al., 2014). Thus, 
traditional risk factors and HIV-specific factors may contribute to the development of 
insomnia among people with HIV. 
However, serum levels of CD-4+ T cell count and HIV-1 RNA viral load do not 
reflect the viral burden in the central nervous system (CNS), which ART regimens do not 
efficiently infiltrate due to their inability to penetrate the blood brain barrier (Dahl et al., 
2014). Because of this, the CNS is viewed as a reservoir of HIV infection, leading to the 
following consequences: (1) a release of viral products (neurotoxins) from infected cells in 
the CNS; (2) an inducement of the inflammatory response; and (3) a positive feedback 
cycle produced by the neurotoxins and inflammatory mediators, causing escalating 
damage, especially to dopaminergic and glutamatergic systems, which are both implicated 
in sleep/wake functioning (Low et al., 2014). Thus, the mechanisms by which HIV affects 
sleep may also lie in the neurotoxic effects of HIV on the CNS.   
Cardiovascular Disease in HIV 
 Epidemiology. The recent decrease in HIV/AIDS-related deaths in people with 
HIV has been accompanied by an increase in non-HIV/AIDS-related deaths, particularly 
deaths due to cardiovascular disease (Feinstein et al., 2016). In fact, in the HIV population, 
CVD is currently among the leading causes of death (Gill et al., 2010). HIV-infected 
individuals exhibit a 48-111% higher risk of AMI than uninfected individuals, even after 
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controlling for traditional CVD risk factors (Durand, Sheehy, Baril, Lelorier, & Tremblay, 
2011; Freiberg et al., 2013; Triant, Lee, Hadigan, & Grinspoon, 2007). A 2012 meta-
analysis found the overall relative risk of CVD among HIV-infected individuals naïve to 
ART to be 61% higher than uninfected individuals and this risk increases to 200% when 
comparing HIV-infected individuals on ART to uninfected individuals (Islam, Wu, 
Jansson, & Wilson, 2012). Even among those without CVD risk factors, HIV-infected 
persons continue to exhibit double the risk of AMI compared to uninfected persons 
(Paisible et al., 2015).  
Pathophysiology. The increased CVD risk in the HIV population is thought to be 
due to both traditional and HIV-specific mechanisms. Regarding traditional mechanisms, 
people with HIV exhibit elevated rates of smoking, hypertension, diabetes, and 
dyslipidemia (Klein, Hurley, Quesenberry, & Sidney, 2002; Triant et al., 2007). In 
addition, evidence of chronic inflammation and altered coagulation have also been 
observed in the HIV-infected individuals. A recent review found that 75% of studies report 
a significant association of inflammatory and coagulation biomarkers with incident CVD 
in people with HIV, independent of traditional CVD risk factors (Vos, Idris, Barth, 
Klipstein-Grobusch, & Grobbee, 2016). 
Regarding HIV-specific mechanisms, several factors related to HIV infection and 
treatment have been implicated in increasing CVD risk. First, viral replication, a low CD-
4+ T cell nadir, and a high CD8 T-cell count have been associated with increased risk of 
MI, independent of traditional CVD risk factors and ART regimen (Lang et al., 2012; 
Silverberg et al., 2014). These results have been experimentally supported by the Strategies 
for Management of Antiretroviral Therapy (SMART) trial, which compared conservative 
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ART (i.e., ART used when CD4+ cell count <250/mm3 and stopped when CD4+ cell count 
>350/mm3) to continuous ART. This trial found HIV-infected individuals in the 
conservative group had an 80% greater risk of CVD than the continuous ART group (El-
Sadr et al., 2006), suggesting that a less than optimal CD-4+ T cell count and a higher viral 
load contribute to CVD risk. Second, evidence suggests the HIV infection itself affects 
many stages of the atherosclerotic process (Lang, Boccara, Mary-Krause, & Cohen, 2015; 
Longenecker, Sullivan, & Baker, 2016). Specifically, HIV infection enhances monocyte 
activation and systemic inflammation and alters cholesterol metabolism. Third, some ART 
regimens are thought to contribute to the elevated CVD risk in HIV. PIs and NRTIs have 
been associated with 11% and 5% increases in CVD risk per exposure year, respectively 
(Islam et al., 2012). The Islam et al. (2012) meta-analysis previously mentioned also reports 
an overall relative risk of incident CVD among HIV-infected adults on ART to be 51% 
higher than HIV-infected adults naïve to ART. In addition, ART regimens have also been 
associated with increasing the likelihood of some traditional CVD risk factors, such as 
dyslipidemia (Crowe et al., 2010). 
The Present Study 
 Given that (1) insomnia/sleep disturbance is a predictor of CVD in the general 
population and that (2) insomnia/sleep disturbance is highly prevalent in the HIV 
population, a key next step is to examine whether insomnia, in part, contributes to the 
elevated CVD risk of people with HIV. Identifying novel and treatable risk factors for CVD 
in HIV could inform the development of new interventions to prevent CVD in this 
vulnerable population. To date, however, no studies have examined whether insomnia 
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predicts incident CVD in people with HIV. Accordingly, the present study sought to 
address this important gap in knowledge.
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CHAPTER 2. METHODS 
 The proposed project required significant modifications following our team’s 
preliminary analyses of the International Classification of Diseases, Ninth Revision (ICD-
9) codes for insomnia disorder, which revealed unacceptably low sensitivity. While the 
proposed project was approved by the Veterans Aging Cohort Study (VACS) principal 
investigator (Dr. Amy Justice) and relevant VACS workgroups, it was on the condition 
that our team perform preliminary analyses examining the sensitivity and specificity of the 
ICD-9 insomnia disorder codes before conducting hypothesis-testing analyses. Members 
of the VACS Cardiovascular Disease and Pulmonary Disease Core Workgroup suspected 
that the ICD-9 codes may have low sensitivity, which was confirmed by our preliminary 
analyses (see Baseline Insomnia Symptoms section). Thus, it was not appropriate to use 
the ICD-9 insomnia disorder codes to determine baseline insomnia status. Nonetheless, my 
hypotheses could still be tested by using an assessment of insomnia symptoms in the VACS 
questionnaire data, which was the alternative approach recommended by Dr. Justice. The 
change in the definition of baseline insomnia resulted in a number of necessary 
modifications to the methods. These changes are detailed in the sections below following 
descriptions of the originally proposed methods. The only modification that was necessary 
to the hypotheses was replacing “insomnia disorder” with “insomnia symptoms”. The 
updated hypotheses are: 
Hypothesis 1: Baseline insomnia symptoms will be an independent predictor of 
incident atherosclerotic CVD among all Veterans in the VACS9 cohort (N = 6,148). 
Hypothesis 2: Baseline insomnia symptoms will be an independent predictor of 
incident atherosclerotic CVD among uninfected Veterans in the VACS9 cohort (n = 3,010). 
19 
 
 
Hypothesis 3: Baseline insomnia symptoms will be an independent predictor of 
incident atherosclerotic CVD among HIV-infected Veterans in the VACS9 cohort (n = 
3,138). 
Exploratory Hypothesis: Baseline insomnia symptoms will be a stronger predictor 
of incident atherosclerotic CVD among HIV-infected Veterans than among uninfected 
Veterans. 
Study Design and Sample 
I originally proposed to test my hypotheses in VACS Virtual Cohort (VACS-VC), 
a prospective, multisite cohort of HIV-infected veterans and age-, race/ethnicity-, and 
clinical site-matched uninfected Veterans (Fultz et al., 2006; Justice et al., 2006). In brief, 
VACS-VC participants have been continuously selected for study enrollment since 1998 
using a validated algorithm of the VA national electronic record system (Fultz et al., 2006). 
However, due to concerns regarding the validity of ICD-9 insomnia disorder codes, my 
hypotheses has to be tested in the VACS9 cohort instead. VACS9, a subsample of the 
VACS-VC cohort, is comprised of Veterans who completed a battery of self-report 
questionnaires at their time of enrollment (Womack et al., 2017). As with other VACS9 
projects, the baseline period for this project was defined as –ever to +6 months of the 
enrollment date. Of note, specific dates are not used to define the baseline period, as 
VACS9 undergoes continuous enrollment throughout the entire study period starting in 
June of 2002. In this study, all participants were followed until the occurrence of an 
atherosclerotic CVD event or the end of the follow-up period (December 31, 2011). VACS 
has been approved by the University of Pittsburgh, Yale University, and West Haven VA 
Medical Center institutional review boards. 
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VACS9 utilizes data from a number of sources. All variables originated from either 
the VA self-report battery or the VA laboratory, pharmacy, clinical, administrative, or 
immunology case registry data. The one exception to this was the outcome variable, which 
originated from VA and Medicare administrative data and the VA fee-for-service data. 
A total of 7,515 Veterans have been enrolled in VACS9. To this cohort, our team 
applied the following exclusion criteria: (1) pre-existing CVD (n = 1,178), defined as the 
presence of an ICD-9 code for AMI, unstable angina, cardiovascular revascularization, 
stroke or transient ischemic attack, peripheral vascular disease, or heart failure during the 
baseline period (Armah et al., 2014; Freiberg et al., 2013); (2) uninfected participants with 
at least one of viral load, CD4 cell count, or ART regimen present (n = 43); (3) participants 
with a baseline date after December 28, 2011 (n = 20); (4) coding errors (i.e., the last 
follow-up date on or before the enrollment date (n = 11); and (5) participants missing 
insomnia questionnaire data (n = 115). Thus, the final sample consisted of 6,148 Veterans.  
Although originally proposed, I was unable to exclude Veterans with baseline sleep 
apnea because the performance of the ICD-9 sleep apnea codes (327.20, 327.21, 327.23, 
327.24, 327.26, 327.27, 327.29, 780.51, 780.53, 780.57) against the VACS9 yes-no sleep 
apnea item (“Has a doctor ever told you that you have any of the following lung or 
breathing conditions? Sleep apnea?”) indicated high specificity for the uninfected (99.4%) 
and HIV-infected (99.6%) cohorts but unacceptably low sensitivity for these groups 
(22.2% and 11.7%, respectively). 
Measures and Procedures 
Baseline Insomnia Symptoms. Originally, I planned to classify participants as 
having a baseline insomnia disorder if they have at least one inpatient or two outpatient 
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ICD-9 codes for insomnia disorder (307.40, 307.41, 307.42, 307.49, 327.00, 327.01, 
327.02, 327.09, 780.50, 780.52, 780.59) in VA administrative data during the baseline 
period. Our preliminary analyses evaluating the performance of the ICD-9 insomnia 
disorder codes against the VACS9 insomnia item (i.e., the presence of difficulty falling or 
staying asleep during the past four weeks) indicated high specificity; however, these 
analyses also revealed unacceptably low sensitivity of the ICD-9 codes. In the uninfected 
cohort, the ICD-9 codes had a specificity of 97.2% and a sensitivity of 7.8%. In the HIV-
infected cohort, they had a specificity of 98.0% and a sensitivity of 4.3%. These results 
indicate that the ICD-9 insomnia disorder codes identified only 7.8% and 4.3% of 
participants with self-reported difficulty falling or staying asleep in the past month in the 
uninfected and HIV-infected cohorts, respectively. Our team and the VACS investigators 
agreed that using the ICD-9 codes would result in an unacceptably high degree of 
misclassification (i.e., participants with insomnia symptoms coded as no for insomnia 
status). 
Consistent with the recommendation of the VACS principal investigator, the 
present study instead used the insomnia symptoms item from the VACS HIV Symptom 
Index, which was included in VACS9 self-report battery administered at the time of 
enrollment. The HIV Symptom Index is a 20-item, self-report questionnaire designed to 
assess the frequency and bother of common symptoms in HIV-infected patients exposed 
to multidrug ART and protease inhibitors (Justice et al., 2001). Participants were asked to 
indicate what response best described their experience of each symptom over the past four 
weeks using the following options: 0 = “I do not have this symptom” or “I have this 
symptom and…” 1 = “it doesn’t bother me”, 2 = “it bothers me a little”, 3 = “it bothers 
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me”, 4 = “it bothers me a lot”. In the present study, responses to the insomnia item – 
“Difficulty falling or staying asleep?” – were used to create a 5-level insomnia symptoms 
variable. From this variable, four dummy coded variables were created with the “no 
symptoms” group as the reference category. 
Baseline HIV Status. Consistent with prior VACS reports, participants were 
classified as HIV-infected if one inpatient or two outpatient ICD-9 codes for AIDS (042), 
asymptomatic HIV (V08), and related diagnostic code groups (488-490) were present in 
the VA administrative data and confirmed in the VA Immunology Case Registry during 
the baseline period (Fultz et al., 2006). All other veterans were classified as uninfected. 
Incident Atherosclerotic CVD. In the original proposal, incident AMI was the 
outcome variable. However, due to the smaller sample size of VACS9, there was a low 
number of AMIs (<10) in several of the cells (see Table 1), raising concerns about low 
power and unstable regression coefficients (Concato, Peduzzi, Holford, & Feinstein, 1995; 
Peduzzi, Concato, Feinstein, & Holford, 1995). To increase event counts to acceptable 
levels, the outcome variable was broadened to incident atherosclerotic CVD. 
TABLE 1. Frequencies for Incident Acute Myocardial Infarction by Insomnia 
Symptoms Level in the VACS9 Cohort (N = 6,148) 
 I do not 
have this 
symptom. 
It doesn’t 
bother me. 
It bothers 
me a little. 
It bothers 
me. 
It bothers 
me a lot. 
Entire  
Cohort  
60 10 36 25 15 
Uninfected 
Cohort 
33 3 13 14 6 
HIV-Infected 
Cohort 
27 7 23 11 9 
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Incident atherosclerotic CVD is a composite variable that counts any of the 
following as events during the follow-up period: AMI, coronary artery revascularization, 
or stroke. Data for these events originated from VA and Medicare administrative data and 
VA fee-for-service data. First, incident AMI was defined using ICD-9 410.X codes. The 
use of AMI code 410 has shown strong agreement with adjudicated AMI outcomes in the 
Cardiovascular Health Study (Ives et al., 1995). Second, incident coronary artery 
revascularization was defined using ICD-9 procedural codes for PCI (00.66, 36.01, 36.02, 
36.06, 36.07, 92977, 92978, 92980, 92981, 92982, 92995) or CABG (33510, 33517, 
33518, 33519, 33533, 33534, 33535). Third, incident stroke was defined using the 
following ICD-9 codes: 433.01, 433.11, 433.91, 434.01, 434.11, 434.91, 436.00, 438.00, 
438.11, 438.19, 438.20, 438.21, 438.22, 438.41, 438.50, 438.60, 438.81, 438.82, 438.84, 
438.89, 438.90. 
Covariates. Analyses included covariates from five categories: demographic 
variables, cardiovascular risk factors, additional potential confounders, depressive 
symptoms and medications, and HIV-specific factors. 
Demographic variables are age (years), sex (0 = male; 1 = female), and 
race/ethnicity (0 = White, Hispanic, and Other; 1 = African American). These variables 
were computed from the VACS9 self-report questionnaire data obtained at enrollment 
(Justice et al., 2006).  
Cardiovascular risk factors are hypertension, diabetes, body mass index (BMI), 
smoking, total cholesterol, and statin use. Hypertension was defined using VA clinical 
(systolic and diastolic blood pressures) and pharmacy data (antihypertensive medication) 
pulled from the encounter closest to the enrollment date during the baseline period. 
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Hypertension was coded as no hypertension (<140/90 mmHg and no antihypertensive 
medication [reference]), controlled hypertension (<140/90 mmHg with antihypertensive 
medication), or uncontrolled hypertension (≥140/90 mmHg; Chobanian et al., 2003). 
Diabetes was defined using VA laboratory, pharmacy, and administrative data based on a 
previously validated metric incorporating glucose measurements, diabetes medication use, 
and/or at least one inpatient or two outpatient ICD-9 codes for diabetes during the baseline 
period (Butt et al., 2004). BMI was defined using VA clinical data pulled from the 
encounter closest to the enrollment date during the baseline period. Smoking (never 
[reference], current, and former smoker) was computed from the VACS9 self-report 
questionnaire data obtained at enrollment. Total cholesterol was defined using VA 
laboratory data and statin use was defined using VA pharmacy data from the encounter 
closest to the enrollment date during the baseline period. 
Additional potential confounders are hepatitis C infection, renal disease, anemia, 
alcohol use, and cocaine use. Hepatitis C infection was defined using VA laboratory data 
(hepatitis c virus antibody test) or VA administrative data (ICD-9 codes) during the 
baseline period. Hepatitis C infection was coded as present if a participant had a positive 
hepatitis c virus antibody test or at least 1 inpatient or 2 outpatient ICD-9 codes for hepatitis 
c infection (Butt et al., 2009). Renal disease was defined using VA laboratory data for 
glomerular filtration rate (eGFR), an indicator of kidney function, from the encounter 
closest to the enrollment date during the baseline period. Anemia was defined using VA 
laboratory data for hemoglobin from the encounter closest to the enrollment date during 
the baseline period. Alcohol use was defined using self-report questionnaire data obtained 
at enrollment (Alcohol Use Disorders Identification Test [AUDIT]) and VA administrative 
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data (ICD-9 codes) during the baseline period (Crawford, Fulton, Swinkels, Beckham, & 
Calhoun, 2013). Alcohol use was coded 0 = no current use or non-hazardous use or 1 = 
hazardous use or alcohol abuse/dependence disorder (291.0, 291.2, 291.3, 291.8, 291.81, 
291.89, 303.00, 303.01, 303.02, 303.03, 303.90, 303.91, 303.92, 303.93, 305.0, 305.01, 
305.02, 305.03, 357.5, 571.1, 571.2, 571.3, V11.3). Cocaine use was defined using 
responses to the enrollment questionnaire item, “For each of the following drugs, please 
mark the box that best indicates how often in the past year you used each drug. Cocaine or 
crack,” as 0 = never tried or no use in last month or 1 = less than once a month, 1-3 times 
a month, 1-3 times a week, 4-6 times a week, or every day. In addition, participants with 
an ICD-9 code for cocaine use disorder (304.20, 304.21, 304.22, 304.23, 305.60, 305.61, 
305.62, 305.63) during the baseline period were also coded as 1.  
Depressive symptoms and medications were also included as covariates. Originally, 
I proposed to include the following in a prescription sleep medication use variable: non-
benzodiazepines, benzodiazepines, serotonin receptor agonists, dibenzothrazepines, and 
miscellaneous other medications used to treat insomnia. However, after re-reviewing the 
medication lists, the team decided to focus solely on non-benzodiazepines, given their 
higher specificity for sleep problems than the other medication categories. Non-
benzodiazepine sleep medication use was defined using VA pharmacy data from the 
encounter closest to the enrollment date during the baseline period (see Table 2). I 
originally proposed to define depressive disorders using ICD-9 codes for major depressive 
disorder and dysthymia. However, because the VACS9 self-report questionnaire battery 
included the reliable and valid Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, 
& Williams, 2001), I decided to use the PHQ-9 total score, as it provided a continuous 
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measure of depressive symptoms and should capture participants with undiagnosed 
depression. The team also added antidepressant medication use as a covariate, which was 
defined using VA pharmacy data for the encounter closest to the enrollment date during 
the baseline period. Three separate dichotomous variables were computed based on the 
type of antidepressant medication – selective serotonin reuptake inhibitors (SSRI), tricyclic 
antidepressant (TCA), and miscellaneous other antidepressants. 
TABLE 2. List of Non-Benzodiazepine Prescription Sleep Medications 
Generic Name Brand Name 
Zolpidem Ambien, Ambien CR, Edluar, Intermezzo, 
Stilnox, Stilnoct, Sublinox, Hypnogen, 
Zonadin, Sanval, Zolsana, Zolpimist, 
Zolfresh 
Zaleplon Sonata, Starnoc, Andante 
Eszopiclone Estorra, Lunesta 
Indiplon-IR, Indiplon-MR -- 
 
HIV-specific factors are HIV-1 RNA levels, CD-4+ T cell count, and ART regimen. 
HIV-1 RNA levels and CD-4+ T cell count were defined using VA laboratory data from 
the encounter closes to the enrollment date during the baseline period. ART regimen was 
defined using VA pharmacy data from the encounter closest to the enrollment date during 
the baseline period. ART regimen was coded as 0 = no ART regimen or 1 = any type of 
ART regimen (e.g., NRTI plus PI, NRTI plus NNRTI, or other regimen). 
Data Analysis 
 VACS9 is a federally protected data source with access granted only to those 
working on-site within the VACS team. Due to this added security, I did not have direct 
access to the VACS9 dataset or new data that was pulled for the proposed project (e.g., 
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sleep disorder diagnoses and prescription sleep medication use). Instead, I worked closely 
with VACS biostatisticians by designing and directing all data pulls and statistical analyses, 
interpreting outputs and results, and constructing tables. Communication with the VACS 
team occurred via bimonthly calls and emails between calls during the project period. 
 Frequencies for categorical variables and medians and 1st and 3rd quartiles for 
continuous variables were examined to assess whether values were within expected ranges 
(see Table 3). Chi-square tests were conducted to determine whether there were differences 
between uninfected and HIV-infected Veterans in insomnia symptoms and incident 
atherosclerotic CVD. A chi-square test was also conducted to determine whether there were 
differences between Veterans with and without non-benzodiazepine sleep medication use 
in insomnia symptoms. Significant chi-square tests were followed by examining the 
contributions (i.e., [observed – expected]2/expected) of each cell to the total chi-square 
(i.e., sum of each cells contribution). This approach was recommended over the use of post-
hoc pairwise comparisons by the VACS biostatisticians.
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TABLE 3. Characteristics of the VACS9 Participants Stratified by HIV Status 
 Entire 
Cohort 
(N = 6,148) 
Uninfected 
Cohort 
(n = 3,010) 
HIV-infected 
Cohort 
(n = 3,138) 
Demographic Variables    
Age, Years 49.2  
[43.7, 54.7] 
49.6  
[44.0, 54.9] 
49.0  
[43.4, 54.6] 
Sex, % Male 5,794 (94.2) 2,747 (91.3) 3,047 (97.1) 
Race/ethnicity, % African American 4,012 (65.3) 1,936 (64.3) 2,076 (66.2) 
Income, < $12,000/year 2,703 (45.5) 1,195 (41.3) 1,508 (49.4) 
    
Cardiovascular Risk Factors    
Hypertensiona    
% None 2,408 (39.2) 1,023 (34.1) 1,385 (44.2) 
% Controlled 2,162 (35.2) 1,115 (37.1) 1,046 (33.4) 
% Uncontrolled 1,571 (25.6) 866 (28.8) 705 (22.5) 
Diabetes, % 992 (16.1) 557 (18.5) 435 (13.9) 
Body Mass Index,a % ≥ 30 kg/m2 1,648 (26.9) 1,190 (39.8) 458 (14.6) 
    
Smokinga    
% Current 3,033 (49.8) 1,395 (47.1) 1,638 (52.4) 
% Former 1,463 (24.0) 731 (24.7) 732 (23.4) 
% Never 1,592 (26.1) 838 (28.3) 754 (24.1) 
Total Cholesterol,a % ≥ 200 mg/dL 1,789 (31.1) 973 (35.0) 816 (27.4) 
Statin Use, % 1,130 (18.4) 659 (21.9) 471 (15.0) 
    
Additional Potential Confounders    
Hepatitis C infection, % 2,116 (34.4) 730 (24.3) 1,386 (44.2) 
Renal Disease,a  eGFR < 60 
mL/min/1.73m2 
308 (5.1) 132 (4.5) 176 (5.6) 
Anemia,a %  Hemoglobin < 12 g/dL 539 (9.0) 142 (4.9) 397 (12.7) 
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TABLE 3. continued 
Alcohol use,a 
 %  Hazardous/Abuse/Dependence 
2,446 (39.9) 1,237 (41.2) 1,209 (38.7) 
Cocaine Use,a % 1,199 (20.1) 508 (17.4) 691 (22.7) 
    
Depressive Symptoms and 
Medications 
   
Non-benzodiazepine  
Sleep Medication 
406 (6.6) 196 (6.5) 210 (6.7) 
PHQ-9,a % Total Score ≥ 10 1,284 (21.1) 602 (20.2) 682 (21.9) 
Antidepressant Medication    
% SSRI 2,003 (32.6) 950 (31.6) 1,053 (33.6) 
% Tricyclic 1,061 (17.3) 430 (14.3) 631 (20.1) 
% Miscellaneous 2,044 (33.2) 1,014 (33.7) 1,030 (32.8) 
    
HIV-Specific Factors    
HIV-1 RNA Levels,a  
% ≥ 500 copies/mL 
-- -- 1,515 (48.4) 
CD-4+ T cell count a    
% < 200 mm3 -- -- 695 (22.2) 
% 201-499 mm -- -- 1,445 (46.3) 
% ≥ 500 mm3 -- -- 984 (31.5) 
ART regimen, % -- -- 2,504 (79.8) 
Note. Continuous variables are presented as median [first quartile, third quartile], and categorical 
variables are presented as n (%). 
VACS = Veterans Aging Cohort Study; HIV = human immunodeficiency virus; PHQ-9 = Patient 
Health Questionnaire-9; SSRI = selective serotonin reuptake inhibitor; ART = antiretroviral 
therapy. 
aThe following variables had fewer than 6,148 participants due to missing data (n missing, %): 
income (200, 3.3), hypertension (8, 0.1), BMI (28, 0.5), smoking (60, 1.0), total cholesterol (390, 
6.3), renal disease (90, 1.5), anemia (131, 2.1), alcohol use (17, 0.3), cocaine use (189, 3.1), PHQ-
9 total score (50, 0.8), HIV-1 RNA levels (5, 0.1), and CD-4+ T cell count  (14, 0.4). 
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 Cox proportional hazards models were constructed to test whether baseline 
insomnia symptoms independently predicted incident atherosclerotic CVD in the entire 
VACS9 cohort (Hypothesis 1). Cox models examine the effect of the independent variable, 
in the presence of covariates, on the time to the dependent variable or event. The models 
were structured in such a way that Models 1-3 hierarchically added the main covariates. 
Models 4a-4c each added one additional covariate to Model 3, and Model 5 included all 
three additional covariates. Specifically, Model 1 (demographic variables) included age, 
sex, and race/ethnicity. Model 2 (cardiovascular risk factors) included the Model 1 
covariates plus hypertension, diabetes, BMI, smoking, total cholesterol, and statin use. 
Model 3 (additional potential confounders) included the Model 2 covariates plus hepatitis 
C infection, renal disease, anemia, alcohol use, and cocaine use. Model 4’s included the 
Model 3 covariates plus non-benzodiazepine sleep medication use (4a), PHQ-9 total score 
(4b), or the three antidepressant medication use variables (4c). Lastly, Model 5 (all 
covariates) included the Model 3 covariates plus non-benzodiazepine use, PHQ-9 total 
score, and antidepressant use variables. 
Cox proportional hazards models were also used to test whether baseline insomnia 
symptoms independently predicted incident atherosclerotic CVD in the VACS9 uninfected 
(Hypothesis 2) and HIV-infected (Hypothesis 3) cohorts. The modeling for Hypothesis 2 
is identical to that of Hypothesis 1, while the modeling for Hypothesis 3 included one 
additional set of main covariates. Specifically, Model 4 (HIV-specific factors) included the 
Model 3 covariates plus HIV-1 RNA levels, CD-4+ T cell count, and ART regimen. 
Consequently, Model 5’s included the Model 4 covariates plus non-benzodiazepine sleep 
medication use (5a), PHQ-9 total score (5b), or the three antidepressant medication use 
31 
 
  27 
variables (5c). Lastly, Model 6 (all covariates) included the Model 4 covariates plus non-
benzodiazepine use, PHQ-9 total score, and antidepressant use variables.  
To evaluate whether baseline insomnia symptoms were a stronger predictor of 
incident atherosclerotic CVD among HIV-infected Veterans than uninfected Veterans 
(Exploratory Hypothesis), the HIV status main effect and HIV status x insomnia symptoms 
cross-product interaction term were added to Model 3 involving the entire VACS9 cohort. 
For Hypothesis 1-3, I present the overall p-value and pairwise comparison hazard 
ratios (HRs) and p-values for insomnia symptoms predicting incident atherosclerotic CVD. 
The overall p-values are omnibus tests of the association of insomnia symptoms, across all 
levels of the variable, with incident atherosclerotic CVD. The pairwise comparison p-
values are tests of whether the HRs for each level of insomnia symptoms (doesn’t bother, 
bothers a little, bothers, and bothers a lot) significantly differs from the HRs for the no 
symptoms reference group. Pairwise comparisons were performed regardless of the overall 
p-value because the bothers and bothers a lot groups may best capture Veterans with 
insomnia disorder, which was the original predictor variable of interest. It is plausible that 
the degree of bother reflects the degree of distress and/or impairment due to insomnia 
symptoms. For the Exploratory Hypothesis, I present the p-value for the HIV status x 
insomnia symptoms cross-product interaction term. This p-value is a test of whether the 
HRs for baseline insomnia symptoms predicting incident atherosclerotic CVD are 
significantly different between uninfected and HIV-infected participants. 
To handle missing data, two data imputation approaches were utilized. First, 
within-person mean imputation was used in the computation of the PHQ-9 total score when 
only one item was missing (n = 243). Second, multiple imputation was used in the Cox 
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models to handle missing data for the covariates (see footnote a to Table 3 for the extent 
of missingness). Multiple imputation is three-step process in which missing values are 
estimated based on a missing-at-random assumption. First, each missing value is estimated 
from a vector of possible values to create a complete dataset. This process is repeated n 
times to create multiple datasets with the first dataset utilizing the first vector value, the 
second utilizing the second vector value, and so on. Using five to ten datasets is typical 
(Horton & Kleinman, 2007). Second, each of the created datasets are analyzed separately, 
resulting in n number of point estimates and standard errors. Third, the results from n 
datasets are combined to create a single point estimate, standard error, and confidence 
interval. The major advantage of multiple imputation over single imputation is the 
allowance of uncertainty in the imputation values, reflected by the combination of multiple 
potential estimated values (Horton & Kleinman, 2007)   
 The event-to-predictor ratio was examined for each model to assess for possible 
overfitting. An event-to-predictor ratio of 10:1 is desirable; lower ratios suggest potentially 
unstable or biased estimates and should be interpreted with caution (Concato et al., 1995; 
Peduzzi et al., 1995). Models involving the entire cohort had the following event-to-
predictor ratios: 52:1 (Model 1), 24:1 (Model 2), 18:1 (Model 3), 17:1 (Model 4a), 17:1 
(Model 4b), 16:1 (Model 4c), and 14:1 (Model 5). Models involving the uninfected cohort 
only had the following ratios: 26:1 (Model 1), 12:1 (Model 2), 9:1 (Model 3), 9:1 (Model 
4a), 9:1 (Model 4b), 8:1 (Model 4c), and 7:1 (Model 5). Models involving the HIV-infected 
cohort only had the following ratios: 26:1 (Model 1), 12:1 (Model 2), 9:1 (Model 3), 8:1 
(Model 4), 8:1 (Model 5a), 8:1 (Model 5b), 7:1 (Model 5c), and 6:1 (Model 6).  
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CHAPTER 3. RESULTS 
Participant Characteristics 
The entire VACS9 cohort consisted of 6,148 Veterans (n = 3,010 uninfected, n = 
3,138 HIV-infected; see Table 3 for participant characteristics). Of note, the median age 
was 49 years. Most participants were men (94%), and a majority of participants were 
African Americans (65%). The prevalence of cardiovascular risk factors was generally 
high, with 61% of participants with hypertension, 16% with diabetes, 27% with obesity, 
50% current smokers, 31% high cholesterol, and 18% on a statin. The prevalence of 
additional potential confounders was also generally high, with 34% of participants with 
hepatitis C infection, 5% with renal disease, 9% with anemia, 40% with hazardous alcohol 
use, and 20% with cocaine use. In terms of medications, 7% of participants were using 
non-benzodiazepine sleep medications, while 33% and 17% were using SSRI or TCA 
antidepressants, respectively. 21% of the sample scored ≥10 on the PHQ-9, a cut-off score 
indicative of a potential depressive disorder (Manea, Gilbody, & McMillan, 2012). 
Additionally, in the HIV-infected cohort, 48% had an HIV-1 RNA level ≥ 500, 22% a CD-
4+ T cell count < 200, and 80% on an ART regimen. 
Baseline Insomnia Symptoms 
 The participant distribution across levels of insomnia symptoms is displayed in 
Table 4. For both cohorts, the highest frequency was in the no symptoms group, and the 
lowest frequency was in the doesn’t bother group. A chi-square test revealed that there 
were significant differences between uninfected and HIV-infected Veterans in insomnia 
symptoms (χ2 = 11.019, p = .026). Examining the cell contributions to the chi-square total 
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indicated that uninfected participants had slightly higher rates of no symptoms (43.9% vs. 
40.7%) and slightly lower rates of doesn’t bother (7.4% vs. 9.2%) than HIV-infected 
participants. Another chi-square test revealed that there were significant differences 
between Veterans with and without non-benzodiazepine sleep medication use in insomnia 
symptoms (χ2 = 192.93, p < .001). Examining the cell contributions indicated that 
participants with non-benzodiazepine use had much lower rates of no symptoms (17.4% 
vs. 44.0%) and much higher rates of bother (24.6% vs. 14.5%) and bothers a lot (32.3% vs. 
12.9%) than those without non-benzodiazepine use, as was expected. 
TABLE 4. Frequencies for Insomnia Symptoms Levels and Incident Atherosclerotic 
CVD Events in the VACS9 Cohort 
Insomnia Symptoms 
Total Cases 
Incident 
Atherosclerotic CVD 
Cases 
No. % No. % 
Entire Cohort  
(N = 6,148) 
-- -- 362 5.9 
No Symptoms 2,598 42.3 155 6.0 
Doesn’t Bother 513 8.3 22 4.3 
Bothers a Little 1,231 20.0 78 6.3 
Bothers 932 15.2 53 5.7 
Bothers a Lot 874 14.2 54 6.2 
     
Uninfected Cohort  
(n = 3,010) 
-- -- 181 6.0 
No Symptoms 1,321 43.9 85 6.4 
Doesn’t Bother 224 7.4 8 3.6 
Bothers a Little 582 17.5 40 6.9 
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Incident Atherosclerotic CVD Events 
 The median follow-up time was 8.2 years (1st quartile: 4.7, 3rd quartile: 8.9). During 
this follow-up period, 362 atherosclerotic CVD events were identified – 181 in the 
uninfected cohort and 181 in the HIV-infected cohort. A chi-square test revealed that the 
CVD event rate did not differ between uninfected (6.0%) and HIV-infected (5.8%) 
participants (χ2 = .125, p = .723). As can be seen in Table 4, only one cell had CVD event 
counts <10. Consequently, caution should be used when interpreting comparisons 
involving the doesn’t bother group in the uninfected cohort, given that this estimate may 
not be stable. CVD event rates ranged from 3.6% to 7.5% (see Table 4), with lowest rate 
in the doesn’t bother group in the uninfected cohort and the highest rate in the bothers a lot 
group in the HIV-infected cohort. 
 
 
TABLE 4. continued 
Bothers 460 15.3 28 6.1 
Bothers a Lot 423 14.1 20 4.7 
     
HIV-Infected Cohort  
(n = 3,138) 
-- -- 181 5.8 
No Symptoms 1,277 40.7 70 5.5 
Doesn’t Bother 289 9.2 14 4.8 
Bothers a Little 649 20.7 38 5.9 
Bothers 472 15.0 25 5.3 
Bothers a Lot 451 14.4 34 7.5 
Note. CVD = cardiovascular disease; VACS = Veterans Aging Cohort Study; HIV = human 
immunodeficiency virus. 
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Hypothesis 1: Entire VACS9 Cohort 
 My first hypothesis that baseline insomnia symptoms will be an independent 
predictor of incident atherosclerotic CVD in the entire VACS9 cohort was not supported 
(see Table 5). The omnibus test of the association of insomnia symptoms, across all levels, 
with incident atherosclerotic CVD (overall p-value) was not significant for Models 1 (p = 
.175), 2 (p = .286), 3 (p = .203), 4a (p = .242), 4b (p = .288), 4c (p = .274), and 5 (p = .268). 
Similarly, for Models 1-5, none of the pairwise comparisons between no symptoms and 
the other four insomnia symptom levels (doesn’t bother, bothers a little, bothers, and 
bothers a lot) were significant. An unexpected, though non-significant (p-value range: 
.055-.191), observation is that the HRs for the doesn’t bother-no symptoms comparison 
tended to fall below 1.00, suggesting that the doesn’t bother group may have a lower risk 
of atherosclerotic CVD than the no symptoms group. 
TABLE 5. Baseline Insomnia Symptoms Predicting Incident Atherosclerotic CVD in 
the Entire VACS9 Cohort (N = 6,148) 
Factor HR (95% CI) p-value 
 
Model 1: Demographic Variables 
 
.175 
No Symptoms 1.00 -- 
Doesn’t Bother 0.74 (0.47-1.16) .191 
Bothers a Little 1.18 (0.90-1.55) .243 
Bothers 1.10 (0.80-1.50) .569 
Bothers a Lot 1.28 (0.94-1.75) .120 
 
Model 2: Cardiovascular Risk Factors 
 
.286 
No Symptoms 1.00 -- 
Doesn’t Bother 0.70 (0.45-1.10) .123 
Bothers a Little 1.09 (0.82-1.43) .557 
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TABLE 5. continued 
Bothers 0.99 (0.72-1.35) .930 
Bothers a Lot 1.19 (0.87-1.63) .288 
 
Model 3: Additional Potential Confounders 
 
.203 
No Symptoms 1.00 -- 
Doesn’t Bother 0.67 (0.73-1.05) .083 
Bothers a Little 1.09 (0.82-1.43) .560 
Bothers 0.98 (0.71-1.34) .881 
Bothers a Lot 1.19 (0.87-1.63) .285 
 
Model 4a: Non-Benzodiazepine Medication 
 
.242 
No Symptoms 1.00 -- 
Doesn’t Bother 0.67 (0.43-1.05) .083 
Bothers a Little 1.07 (0.81-1.41) .625 
Bothers 0.96 (0.69-1.32) .784 
Bothers a Lot 1.16 (0.84-1.60) .372 
 
Model 4b: PHQ-9 Total Score 
 
.288 
No Symptoms 1.00 -- 
Doesn’t Bother 0.65 (0.41-1.02) .063 
Bothers a Little 1.04 (0.78-1.38) .790 
Bothers 0.89 (0.63-1.26) .502 
Bothers a Lot 1.02 (0.69-1.50) .933 
 
Model 4c: Antidepressant Medication 
 
.274 
No Symptoms 1.00 -- 
Doesn’t Bother 0.66 (0.42-1.03) .066 
Bothers a Little 1.04, (0.79-1.38) .765 
Bothers 0.90 (0.65-1.25) .536 
Bothers a Lot 1.07 (0.76-1.49) .709 
38 
 
  27 
TABLE 5. continued 
Model 5: All Covariates  .268 
No Symptoms 1.00  
Doesn’t Bother 0.64 (0.41-1.01) .055 
Bothers a Little 1.01 (0.76-1.34) .948 
Bothers 0.84 (0.59-1.20) .336 
Bothers a Lot 0.95 (0.64-1.42) .814 
Note. Incident atherosclerotic CVD events = 362. The overall p-value is displayed in respective 
model row. 
CVD = cardiovascular disease; VACS = Veterans Aging Cohort Study; HR = hazard ratio; CI = 
confidence interval. 
 
Hypothesis 2: VACS9 Uninfected Cohort 
My second hypothesis that baseline insomnia symptoms will be an independent 
predictor of incident atherosclerotic CVD in the VACS9 uninfected cohort was also not 
supported (see Table 6). Once again, the omnibus test (overall p-value) was not significant 
for Models 1 (p = .291), 2 (p = .361), 3 (p = .350), 4 (p = .349), 5 (p = .110), 6 (p = .312), 
and 7 (p = .102). Similarly for Models 1-4, none of the pairwise comparisons between no 
symptoms and the other four insomnia symptom levels (doesn’t bother, bothers a little, 
bothers, and bothers a lot) were significant (p-value range: .051-.811). An unexpected, 
significant result was observed in Model 5 for the pairwise comparison between bothers a 
lot-no symptoms (p = .041). The associated HR suggests that Veterans bothered a lot by 
difficulty falling or staying asleep are at 48% lower risk of incident atherosclerotic CVD 
than Veterans without these symptoms, which was unexpected. However, there is little 
evidence of this inverse association in the simpler models with fewer covariates, which 
major raises concerns about the reproducibility and meaning of this result. Once again, the 
HRs for the doesn’t bother-no symptoms comparison tended to fall below 1.00 (p-value 
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range: .073-.151). Of note, there were only eight cases of incident atherosclerotic CVD in 
the doesn’t bother group, which raises concerns about the stability of these estimates. 
TABLE 6. Baseline Insomnia Symptoms Predicting Incident Atherosclerotic CVD in 
the Uninfected Cohort (n = 3,010)  
Factor HR (95% CI) p-value 
 
Model 1: Demographic Variables 
 
.291 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.59 (0.28-1.21) .151 
 Bothers a Little 1.25 (0.86-1.82) .249 
 Bothers 1.14 (0.74-1.76) .547 
 Bothers a Lot 0.94 (0.57-1.54) .811 
 
Model 2: Cardiovascular Risk Factors 
 
.361 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.58 (0.28-1.19) .136 
 Bothers a Little 1.14 (0.78-1.66) .503 
 Bothers 1.02 (0.66-1.58) .937 
 Bothers a Lot 0.82 (0.50-1.34) .430 
 
Model 3: Additional Potential Confounders 
 
.350 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.56 (0.27-1.15) .115 
 Bothers a Little 1.11 (0.75-1.62) .607 
 Bothers 0.98 (0.63-1.53) .933 
 Bothers a Lot 0.79 (0.48-1.30) .348 
 
Model 4a: Non-benzodiazepine Medication 
 
.349 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.56 (0.27-1.15) .115 
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TABLE 6. continued 
 Bothers a Little 1.09 (0.74-1.61) .648 
 Bothers 0.97 (0.62-1.51) .885 
 Bothers a Lot 0.78 (0.47-1.28) .322 
 
Model 4b: PHQ-9 Total Score 
 
.110 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.51 (0.25-1.07) .075 
 Bothers a Little 1.01 (0.68-1.49) .969 
 Bothers 0.80 (0.50-1.30) .370 
 Bothers a Lot 0.55 (0.30-1.00) 0.51 
 
Model 4c: Antidepressant Medication 
 
.312 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.55 (0.26-1.14) .105 
 Bothers a Little 1.07 (0.73-1.58) .728 
 Bothers 0.95 (0.60-1.49) .809 
 Bothers a Lot 0.73 (0.43-1.25) .255 
 
Model 5: All Covariates 
 
.102 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.51 (0.24-1.07) .073 
 Bothers a Little 0.98 (0.66-1.46) .928 
 Bothers 0.78 (0.48-1.28) .333 
 Bothers a Lot 0.52* (0.28-0.97) .041 
Note. Incident atherosclerotic CVD events = 181. The overall p-value is displayed in respective 
model row. 
CVD = cardiovascular disease; VACS = Veterans Aging Cohort Study; HR = hazard ratio; CI = 
confidence interval. 
*p < .05 
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Hypothesis 3: VACS9 HIV-Infected Cohort 
My third hypothesis that baseline insomnia symptoms will be an independent 
predictor of incident atherosclerotic CVD in the VACS9 HIV-infected cohort was partially 
supported (see Table 7). Again, the omnibus test (overall p-value) was not significant for 
Models 1 (p = .169), 2 (p = .146), 3 (p = .085), 4 (p = .115), 5a (p = .170), 5b (p = .210), 
5c (p = .332), and 6 (p = .325). Similarly, for Models 1-6, none of the pairwise comparisons 
between no symptoms and three of the insomnia symptom levels (doesn’t bother, bothers 
a little, and bothers) were significant (p-value range: .473-.982). In contrast, for Models 1-
5b, a significant result was observed for the pairwise comparison between bothers a lot-no 
symptoms (p-value range: .010-.045). The associated HR suggests that Veterans bothered 
a lot by difficulty falling or staying asleep are at 64-77% greater risk of incident 
atherosclerotic CVD than Veterans without these symptoms. Of note, for Models 5c and 6, 
this relationship slightly attenuated (48 and 54% greater risk) and became nonsignificant 
(p = .094 and .112) after adjustment for antidepressant medication use. 
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TABLE 7. Baseline Insomnia Symptoms Predicting Incident Atherosclerotic CVD in the 
HIV-infected Cohort (n = 3,138)  
 Factor HR (95% CI) p-value 
 
Model 1: Demographic Variables 
 
.169 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.88 (0.49-1.56) .653 
 Bothers a Little 1.12 (0.75-1.66) .578 
 Bothers 1.07 (0.67-1.69) .787 
 Bothers a Lot 1.66* (1.10-2.51) .016 
 
Model 2: Cardiovascular Risk Factors 
 
.146 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.82 (0.46-1.46) .506 
 Bothers a Little 1.04 (0.69-1.55) .859 
 Bothers 1.01 (0.63-1.60) .982 
 Bothers a Lot 1.64* (1.08-2.50) .020 
 
Model 3: Additional Potential Confounders 
 
.085 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.80 (0.44-1.46) .473 
 Bothers a Little 1.11 (0.73-1.67) .631 
 Bothers 1.09 (0.68-1.74) .722 
 Bothers a Lot 1.77* (1.15-2.73) .010 
 
Model 4: HIV-Specific Factors 
 
.115 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.82 (0.45-1.50) .519 
 Bothers a Little 1.11 (0.74-1.68) .608 
 Bothers 1.10 (0.69-1.75) .702 
 Bothers a Lot 1.73* (1.12-2.68) .013 
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TABLE 7. continued 
 
Model 5a: Non-benzodiazepine Medication 
 
.170 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.82 (0.45-1.49) .514 
 Bothers a Little 1.10 (0.73-1.65) .665 
 Bothers 1.07 (0.67-1.71) .781 
 Bothers a Lot 1.66* (1.07-2.59) .023 
 
Model 5b: PHQ-9 Total Score 
 
.210 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.82 (0.45-1.49) .514 
 Bothers a Little 1.11 (0.73-1.69) .631 
 Bothers 1.09 (0.66-1.79) .748 
 Bothers a Lot 1.71* (1.01-2.88) .045 
 
Model 5c: Antidepressant Medication 
 
.332 
 No Symptoms 1.00 -- 
 Doesn’t Bother 0.80 (0.44-1.45) .454 
 Bothers a Little 1.04 (0.69-1.58) .847 
 Bothers 0.96 (0.59-1.55) .862 
 Bothers a Lot 1.48 (0.94-2.33) .094 
Model 6: All Covariates  .325 
 No Symptom 1.00 -- 
 Doesn’t Bother 0.80 (0.44-1.47) .481 
 Bothers a Little 1.05 (0.69-1.60) .818 
 Bothers 0.98 (0.59-1.63) .940 
 Bothers a Lot 1.54 (0.90-2.62) .112 
Note. Incident atherosclerotic CVD events = 181. The overall p-value is displayed in respective 
model row. 
CVD = cardiovascular disease; VACS = Veterans Aging Cohort Study; HR = hazard ratio; CI = 
confidence interval. 
*p < .05 
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Entire VACS9 Cohort – Exploratory Hypothesis 
My exploratory hypothesis that insomnia symptoms will be a stronger predictor of 
incident atherosclerotic CVD among HIV-infected Veterans than among uninfected 
Veterans was not supported. When added to Model 3 in the entire cohort, the HIV status x 
insomnia symptoms interaction term was not significant (p = .128), indicating that the 
overall association of insomnia symptoms with incident atherosclerotic CVD was not 
significantly different in the uninfected and HIV-infected cohorts.
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CHAPTER 4. DISCUSSION 
Summary of Results 
 The overall aim of this study was to examine whether insomnia symptoms are an 
independent predictor of incident atherosclerotic CVD in uninfected and HIV-infected 
Veterans. First, chi-square tests revealed that there were minimal, although significant, 
differences in insomnia symptoms and no differences in incident CVD between uninfected 
and HIV-infected Veterans. Second, Cox models indicated that Hypotheses 1 and 2 were 
not supported; baseline insomnia symptoms did not predict incident CVD in the entire 
VACS9 cohort or in the uninfected cohort. Unexpectedly, uninfected Veterans bothered a 
lot by difficulty falling or staying asleep exhibited a 48% lower risk of incident CVD than 
uninfected Veterans without these symptoms in the model including all covariates. Third, 
Cox models indicated that Hypothesis 3 was partially supported, as HIV-infected Veterans 
bothered a lot by difficulty falling or staying asleep exhibited a 64-77% greater risk of 
incident CVD than HIV-infected Veterans without these symptoms, independent of 
demographic variables, cardiovascular risk factors, additional potential confounders, HIV-
specific factors, non-benzodiazepine sleep medication use, and depressive symptoms. 
However, this relationship was attenuated (48-54% greater risk) and became nonsignificant 
in the presence of antidepressant medication use. No other differences in incident CVD 
were detected between the no symptoms group and the other insomnia symptoms groups 
in the HIV-infected cohort. Lastly, my exploratory hypothesis was not supported. The 
interaction testing whether insomnia symptoms were a stronger predictor of incident CVD 
in the HIV-infected versus uninfected cohort was not significant. Taken together, the 
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present results provide preliminary support that highly bothersome insomnia symptoms 
may be an independent predictor of incident atherosclerotic CVD among HIV-infected 
adults. 
Limitations and Interpretive Considerations 
The present results should be interpreted with caution for a number of reasons. First, 
the insomnia symptoms item was taken from the HIV Symptom Checklist, a questionnaire 
validated in a small sample of 113 HIV-infected Veterans at one VA site (Justice et al., 
2001). This questionnaire was designed to assess the frequency and bother of common 
symptoms in HIV-infected patients exposed to multidrug ART and protease inhibitors; 
thus, it is unclear whether this questionnaire functions similarly in uninfected Veterans. 
Two plausible explanations exist for the null findings in the uninfected cohort. First, the 
HIV Symptom Checklist is not appropriate for and may not be valid in uninfected Veterans. 
Second, it is possible that uninfected and HIV-infected Veterans use the response options 
differently. Specifically, insomnia severity may need to be higher for HIV-infected 
Veterans to give a rating of “bothers a lot”, given that they are likely coping with many 
other bothersome symptoms related to HIV. These response option issues could have 
contributed to the differential associations of insomnia symptoms with incident 
atherosclerotic CVD observed in uninfected and HIV-infected Veterans. Furthermore, in 
the HIV Symptom Checklist validation study (Justice et al., 2001), the psychometric 
properties of the insomnia symptoms item were not directly evaluated. Thus, it is unclear 
whether this item provides a valid assessment of insomnia symptoms in uninfected or HIV-
infected Veterans. Despite these potential issues with the insomnia symptoms assessment, 
the item (1) was deemed preferable to ICD-9 insomnia disorder codes because of their 
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unacceptably low sensitivity and (2) was strongly associated with non-benzodiazepine 
sleep medication use in the expected direction. 
Second, using a single item is not sufficient to capture all of the important aspects 
of insomnia. While the VACS9 insomnia symptoms item assesses difficulty initiating and 
maintaining sleep and distress (i.e., bothersomeness), it misses other insomnia symptoms, 
such as early morning awakening and functional impairment, and it does not measure 
symptom frequency and duration. These issues with content validity could lead to 
misclassification (e.g., coding a Veteran with insomnia symptoms as not having them), 
which could contribute to null results or the underestimation of effect sizes. Single-item 
assessments also tend to have lower reliability than multi-item questionnaires (DeVellis, 
2016), which can make it more difficult to detect true associations. Thus, the null findings 
of the present study may be partially due to the use of a single-item insomnia measure. 
However, the majority of studies involving uninfected adults have used single-item 
insomnia measures (most often, difficulty falling asleep) and have observed positive 
associations with CVD-related outcomes (Li et al., 2014).  
Third, because the most complex Cox models included a large number of 
covariates, some event-to-predictor ratios were lower than the recommended 10:1 (i.e., 
Models 3-5 for the uninfected cohort and Models 3-6 for the HIV-infected cohort). These 
lower ratios suggests that the listed models may be overfitted, which raises concerns about 
the reproducibility of the results in future studies. Overfitted models have a high risk of 
producing unstable regression coefficients, meaning that estimates are based on the 
idiosyncrasies of the original sample and will likely fluctuate with repeated sampling 
(Babyak, 2004). Thus, the unexpected result that uninfected Veterans bothered a lot by 
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difficulty falling or staying asleep are at a lower risk of incident CVD (Model 5 only) may 
be a true finding of an overfitted model in the current VACS9 dataset but may not replicate 
in other datasets. This finding also contradicts the existing literature on the insomnia-CVD 
relationship in the uninfected population (Li et al., 2014; Schwartz et al., 1999; Sofi et al., 
2014), further building the case that this result may be due to overfitting. In contrast, it is 
unlikely that the finding in the HIV-infected cohort are attributable to overfitted models, 
as the result that HIV-infected Veterans bothered a lot by difficulty falling or staying asleep 
are at a higher risk of incident CVD was also detected in simpler, non-overfitted models 
(i.e., Models 1 and 2). 
Fourth, the present study performed a large number of statistical tests with no 
correction for multiple testing applied. Our team decided against applying a correction 
because our power for many comparisons is likely low due to lower CVD event counts. 
Nonetheless, some detected relationships could be type 1 errors. This issue is particularly 
applicable to the uninfected cohort bothers a lot-no symptoms comparison that only 
became significant in Model 5. It is less likely that this issue is of concern for the HIV-
infected findings as the bothers a lot-no symptoms comparison was consistent across 
Models 1-5b. 
Fifth, despite changing the outcome variable from AMI to the broader 
atherosclerotic CVD, event counts were still low in some insomnia symptoms groups. In 
particular, the number of events per insomnia symptoms group in the uninfected cohort 
was less than the suggested ≥10 (Concato et al., 1995; Peduzzi et al., 1995) for the doesn’t 
bother group (8). This raises concern about whether estimates for this group are stable and 
unbiased. 
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Sixth, it is worth noting that including insomnia symptoms, depressive symptoms, 
and their corresponding medications in the most extensively adjusted models may represent 
overadjustment. Removal of the shared variance among these variables could have reduced 
the ability to detect the hypothesized relationships. Thus, the nonsignificant findings for 
HIV-infected Veterans in the bothers a lot-no symptoms comparison in Models 5c and 6 
may be due to overadjustment. 
Seventh, the included sample was made up entirely of Veterans and largely 
included African American males. Such a sample could impede our ability to generalize 
our findings to other populations and could affect our ability to replicate previous literature 
findings. For instance, the existing literature does not include studies of Veterans. In 
addition, little is known about whether psychosocial risk factors, such as insomnia 
symptoms, contribute to CVD risk differentially in African American versus Caucasian or 
Hispanic Americans. It is also important to note that the VACS9 cohort includes high rates 
of substance use diagnoses and a large number of adults with an income <$12,000, which 
could contribute to sample differences that may have affected my ability to replicate the 
results of previous studies. However, it is unlikely that our disproportionately higher 
numbers of males negatively affected the ability to observe the insomnia-CVD relationship 
as previous studies of largely male samples find significant, positive associations between 
subjective sleep complaints and CVD events (Li et al., 2014). 
Fit With Literature and Leading Explanations 
Uninfected Adults. The lack of significant relationships between baseline 
insomnia symptoms and incident atherosclerotic CVD among uninfected Veterans was 
surprising and contrasts with the existing literature. To illustrate, a 1999 meta-analysis 
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found that adults with versus without sleep complaints are 70% more likely to experience 
a CAD event (Schwartz et al., 1999). Similarly, two 2014 meta-analyses found that adults 
with sleep complaints are 45% more likely to experience a total CVD event (AMI, CAD, 
stroke, or CVD-related mortality; Sofi et al., 2014) and that adults with sleep complaints 
are at a 41% increased risk for AMI, a 28% increased risk for CAD, a 55% increased risk 
for stroke, and a 33% increased risk for CVD-related mortality (Li et al., 2014). In addition, 
the one study that examined insomnia disorder found that adults with insomnia disorder 
are at an 81% increased risk of total CVD events (AMI and stroke), a 68% increased risk 
of AMI, and an 85% increased risk of stroke (Hsu et al., 2015). To my knowledge, this is 
the first study to examine the association of insomnia symptoms or insomnia disorder with 
incident CVD in a Veteran sample. 
Conflicting with the existing literature for the uninfected population, I did not 
observe a positive relationship between insomnia symptoms and incident CVD. There are 
at least five plausible explanations for this discrepancy. First, the VACS9 insomnia 
symptoms assessment was from the HIV Symptom Checklist, which may not be 
appropriate or valid for uninfected Veterans. Second, uninfected and HIV-infected 
Veterans may be using the response options of the HIV Symptom Checklist differently. 
Third, it is unknown whether the HIV Symptom Checklist insomnia item provides a valid 
assessment of insomnia symptoms in either uninfected or HIV-infected Veterans. Fourth, 
a single item is insufficient to capture all of the important aspects of insomnia. Fifth, the 
included uninfected sample was made up entirely of Veterans and largely included African 
American males. These possible explanations are discussed in detail in the previous 
section. 
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Also conflicting with the existing literature, I observed an inverse relationship 
between insomnia symptoms and incident CVD in Model 5 for the uninfected Veterans. 
However, this finding was not observed in Models 1-4c and, thus, could be due to an 
overfitted model or a type 1 error. Given that previous literature reports a positive, rather 
than an inverse, relationship and that statistical concerns may be contributing factors, it is 
unlikely that this result will replicate in future studies involving uninfected cohorts. 
HIV-Infected Adults. For the HIV-infected cohort, the present study reports 
findings that conflict with existing literature. Previous reviews have reported a high 
prevalence of sleep disturbance and insomnia symptoms (29-97%) in people with HIV 
(Low et al., 2014; Reid & Dwyer, 2005). In addition, a meta-analysis found the prevalence 
of sleep disturbance to be 58% in the HIV-infected population (Wu et al., 2015), which 
was suspected to be greater than that in the uninfected population (36%; Roth et al., 2006). 
In the present study, I found a significant difference in insomnia symptoms; however, this 
difference was minimal and not as large as expected, given past findings. One potential 
explanation for the smaller than expected difference is that the VACS9 insomnia item did 
not assess some important aspects of insomnia (e.g., early morning awakening, functional 
impairment, symptom frequency and duration), which could limit the ability to detect true 
differences in insomnia prevalence between uninfected and HIV-infected adults. In support 
of this explanation, the Low et al. (2014) meta-analysis found that studies of HIV-infected 
samples using the 19-item Pittsburgh Sleep Quality Index reported higher prevalence rates 
(66-97%) than studies using other measures of sleep disturbance (29-76%). 
The present study also reports findings that are novel. Specifically, the results 
provide preliminary evidence that highly bothersome insomnia symptoms may be an 
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independent predictor of incident atherosclerotic CVD among HIV-infected adults. To my 
knowledge, this is the first study to examine insomnia symptoms as a predictor of CVD-
related events in HIV. While little is known about potential mechanisms underlying the 
insomnia-CVD relationship in the HIV-infected population, research from the uninfected 
population suggests both behavioral (physical inactivity, excessive alcohol use, smoking, 
poor diet) and biological pathways (hypothalamic-pituitary adrenal axis and autonomic 
nervous system dysregulation, chronic inflammation, altered coagulation, and endothelial 
dysfunction; Balbo et al., 2010; Calandra-Buonaura et al., 2016; Haario et al., 2013; 
Hoefelmann et al., 2012; Htoo et al., 2004; Irwin et al., 2015; Jackowska & Steptoe, 2015; 
Kohansieh & Makaryus, 2015). Thus far, research in people with HIV has focused solely 
on inflammation as a biological mechanism and suggests that insomnia is linked to higher 
levels of inflammatory markers implicated in CVD (Gay et al., 2015; Lee et al., 2014; 
Wirth et al., 2015). Research examining the link between insomnia and the other potential 
pathways in HIV is lacking. 
Rather than finding a dose-response relationship between insomnia symptoms and 
incident CVD, I observed a threshold effect, with only the highest level of insomnia 
symptoms exhibiting an increase in CVD risk. The leading potential explanation for this 
finding is that (a) the bothered a lot group may have the highest rate of insomnia disorder 
and that (b) it is insomnia disorder, versus subclinical insomnia symptoms, that is related 
to elevated CVD risk. Supporting this notion, Veterans bothered a lot by difficulty falling 
or staying asleep had the highest rate of non-benzodiazepine sleep medication use (32.3%).
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I also found that the insomnia symptoms-incident CVD relationship in HIV was 
attenuated after adjustment for antidepressant medication use. The leading potential 
explanation for this result, as noted above, is overadjustment. Several antidepressants 
captured by the antidepressant use variables (amitriptyline, doxepin, nortriptyline, 
trimipramine, nefazodone, trazodone, and mirtazapine) are also used to treat insomnia. 
Thus, the antidepressant variables may be additional markers of the presence of insomnia 
disorder (Buysse, 2013; Wichniak, Wierzbicka, & Jernajczyk, 2012; Wilt et al., 2016). 
Finally, the present results suggests that insomnia symptoms are not a stronger 
predictor of incident CVD in HIV-infected versus uninfected Veterans. To my knowledge, 
there are not existing studies that have examined whether the risk of CVD conferred by 
insomnia is different between HIV-infected and uninfected adults. As is discussed above, 
because there are a number of methodological issues with the VACS9 insomnia 
assessment, it is unclear whether this result will replicate in future studies utilizing different 
insomnia assessments. 
Future Directions 
The present investigation has important limitations to be addressed in future 
research. Specifically, future prospective studies should: (1) use a comprehensive insomnia 
symptom measure (e.g., Insomnia Severity Index (Morin, Belleville, Belanger, & Ivers, 
2011) or a structured diagnostic interview assessment (e.g., Structured Interview for Sleep 
Disorders [SIS-D]; Schramm et al., 1993), ideally validated specifically in people with 
HIV; (2) examine measures of subclinical atherosclerosis (e.g., carotid intima-media 
thickness or coronary artery calcification), which would provide continuous outcome 
variables allowing for shorter follow-up periods; (3) utilize samples with greater 
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generalizability (e.g., non-Veteran samples with a greater representation of women); (4) 
exclude participants with sleep apnea to help isolate the insomnia-CVD association (sleep 
apnea is also linked with elevated CVD risk. In addition to these recommendations, future 
studies should address the literature gap regarding potential mechanisms underlying the 
insomnia-CVD relationship in HIV. To address this need, I plan to pursue a dissertation 
with the overall aim of examining the associations of insomnia symptoms with three 
potential biological pathways of CVD in HIV – systemic inflammation, altered 
coagulation, and endothelial dysfunction. 
Conclusion and Implications 
In sum, this prospective cohort study provides preliminary support that highly 
bothersome insomnia symptoms are an independent predictor of incident atherosclerotic 
CVD among HIV-infected Veterans. I found that HIV-infected Veterans bothered a lot by 
difficulty falling or staying asleep have greater CVD risk than HIV-infected Veterans 
without these symptoms. This study failed to replicate previous findings that insomnia 
symptoms are predictive of incident CVD in uninfected adults, which may be due to issues 
related to the validity of the insomnia symptoms assessment. Given the novelty of 
examining insomnia as a predictor of incident CVD in HIV and the limitations of the 
present study, future research is needed to better elucidate the association between 
insomnia and future CVD in this population. Ultimately, research examining the insomnia-
CVD relationship in people with HIV could lead to the identification of a novel and 
treatable risk factor for CVD in HIV and could inform the development of new 
interventions to prevent CVD in this vulnerable population.
55 
 
  27 
REFERENCES 
Allavena, C., Guimard, T., Billaud, E., De la Tullaye, S., Reliquet, V., Pineau, S., . . . 
Sommei, C. O.-P. L. T. (2016). Prevalence and Risk Factors of Sleep Disturbance 
in a Large HIV-Infected Adult Population. Aids and Behavior, 20(2), 339-344. 
doi: 10.1007/s10461-015-1160-5 
American Academy of Sleep Medicine. (2014). The International Classification of Sleep 
Disorders, (ICSD-3) (3rd Ed.). Westchester, IL: American Academy of Sleep 
Medicine. 
American Heart Association. (2017, March 2017). Cardiac procedures and surgeries. 
from 
http://www.heart.org/HEARTORG/Conditions/HeartAttack/TreatmentofaHeartAt
tack/Cardiac-Procedures-and-Surgeries_UCM_303939_Article.jsp - .WWUm-
NwpDRY 
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental 
Disorders, 5th edition (DSM-5) (5 ed.). Arlington, VA: American Psychiatric 
Association. 
Armah, K. A., Chang, C. C., Baker, J. V., Ramachandran, V. S., Budoff, M. J., Crane, H. 
M., . . . Freiberg, M. S. (2014). Prehypertension, hypertension, and the risk of 
acute myocardial infarction in HIV-infected and -uninfected veterans. Clinical 
Infectious Diseases, 58(1), 121-129. doi: 10.1093/cid/cit652 
56 
 
  27 
Babyak, M. A. (2004). What you see may not be what you get: a brief, nontechnical 
introduction to overfitting in regression-type models. Psychosomatic Medicine, 
66(3), 411-421.  
Balbo, M., Leproult, R., & Van Cauter, E. (2010). Impact of Sleep and Its Disturbances 
on Hypothalamo-Pituitary-Adrenal Axis Activity. International Journal of 
Endocrinology, 16. doi: 10.1155/2010/759234 
Baldwin, C. M., Ervin, A. M., Mays, M. Z., Robbins, J., Shafazand, S., Walsleben, J., & 
Weaver, T. (2010). Sleep disturbances, quality of life, and ethnicity: the Sleep 
Heart Health Study. Journal of Clinical Sleep Medicine, 6(2), 176-183.  
Butt, A. A., Fultz, S. L., Kwoh, C. K., Kelley, D., Skanderson, M., & Justice, A. C. 
(2004). Risk of diabetes in HIV infected veterans pre- and Post-HAART and the 
role of HCV coinfection. Hepatology, 40(1), 115-119. doi: 10.1002/hep.20289 
Butt, A. A., Xiaoqiang, W., Budoff, M., Leaf, D., Kuller, L. H., & Justice, A. C. (2009). 
Hepatitis C virus infection and the risk of coronary disease. Clinical Infectious 
Diseases, 49(2), 225-232. doi: 10.1086/599371 
Buysse, D. J. (2013). Insomnia. Journal of the Americal Medical Association, 309(7), 
706-716. doi: 10.1001/jama.2013.193 
Calandra-Buonaura, G., Provini, F., Guaraldi, P., Plazzi, G., & Cortelli, P. (2016). 
Cardiovascular autonomic dysfunctions and sleep disorders. Sleep Medicine 
Reviews, 26, 43-56. doi: 10.1016/j.smrv.2015.05.005 
 
 
57 
 
  27 
Cappuccio, F. P., Cooper, D., D'Elia, L., Strazzullo, P., & Miller, M. A. (2011). Sleep 
duration predicts cardiovascular outcomes: a systematic review and meta-analysis 
of prospective studies. European Heart Journal, 32(12), 1484-1492. doi: 
10.1093/eurheartj/ehr007 
Chen, X. L., Wang, R., Zee, P., Lutsey, P. L., Javaheri, S., Alcantara, C., . . . Redline, S. 
(2015). Racial/Ethnic Differences in Sleep Disturbances: The Multi-Ethnic Study 
of Atherosclerosis (MESA). Sleep, 38(6), 877-U187. doi: 10.5665/sleep.4732 
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. 
L., . . . Natl High Blood Pressure Educ, P. (2003). Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure. Hypertension, 42(6), 1206-1252. doi: 
10.1161/01.HYP.0000107251.49515.c2 
Concato, J., Peduzzi, P., Holford, T. R., & Feinstein, A. R. (1995). Importance of events 
per independent variable in proportional hazards analysis I. Background, goals, 
and general strategy. Journal of Clinical Epidemiology, 48(12), 1495-1501. doi: 
http://dx.doi.org/10.1016/0895-4356(95)00510-2 
Crawford, E. F., Fulton, J. J., Swinkels, C. M., Beckham, J. C., & Calhoun, P. S. (2013). 
Diagnostic efficiency of the AUDIT-C in U.S. veterans with military service since 
September 11, 2001. Drug and Alcohol Dependence, 132(1-2), 101-106. doi: 
10.1016/j.drugalcdep.2013.01.012 
 
 
58 
 
  27 
Crowe, S. M., Westhorpe, C. L. V., Mukhamedova, N., Jaworowski, A., Sviridov, D., & 
Bukrinsky, M. (2010). The macrophage: the intersection between HIV infection 
and atherosclerosis. Journal of Leukocyte Biology, 87(4), 589-598. doi: 
10.1189/jlb.0809580 
Dahl, V., Peterson, J., Fuchs, D., Gisslen, M., Palmer, S., & Price, R. W. (2014). Low 
levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of 
suppressive therapy are associated with local immune activation. Aids, 28(15), 
2251-2258. doi: 10.1097/qad.0000000000000400 
DeVellis, R. F. (2016). Scale development: Theory and applications (Vol. 26): Sage 
publications. 
Drake, C. L., Pillai, V., & Roth, T. (2014). Stress and Sleep Reactivity: A Prospective 
Investigation of the Stress-Diathesis Model of Insomnia. Sleep, 37(8), 1295-1304. 
doi: 10.5665/sleep.3916 
Durand, M., Sheehy, O., Baril, J. G., Lelorier, J., & Tremblay, C. L. (2011). Association 
Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial 
Infarction: A Cohort and Nested Case-Control Study Using Quebec's Public 
Health Insurance Database. Journal of Acquired Immune Deficiency Syndromes, 
57(3), 245-253. doi: 10.1097/QAI.0b013e31821d33a5 
El-Sadr, W. M., Lundgren, J. D., Neaton, J. D., Gordin, F., Abrams, D., Arduino, R. 
C., . . . Strategies Management, A. (2006). CD4+count-guided interruption of 
antiretroviral treatment. New England Journal of Medicine, 355(22), 2283-2296.  
Espie, C. A. (2007). Understanding insomnia through cognitive modelling. Sleep 
Medicine, 8, S3-S8. doi: 10.1016/s1389-9457(08)70002-9 
59 
 
  27 
Falk, E., Shah, P. K., & Fuster, V. (1995). Coronary Plaque Disruption. Circulation, 
92(3), 657-671.  
Feinstein, M. J., Bahiru, E., Achenbach, C., Longenecker, C. T., Hsue, P., So-Armah, 
K., . . . Lloyd-Jones, D. M. (2016). Patterns of Cardiovascular Mortality for HIV-
Infected Adults in the United States: 1999 to 2013. American Journal of 
Cardiology, 117(2), 214-220. doi: 10.1016/j.amjcard.2015.10.030 
Fernandez-Mendoza, J., Vgontzas, A. N., Liao, D. P., Shaffer, M. L., Vela-Bueno, A., 
Basta, M., & Bixler, E. O. (2012). Insomnia With Objective Short Sleep Duration 
and Incident Hypertension The Penn State Cohort. Hypertension, 60(4), 929-+. 
doi: 10.1161/hypertensionaha.112.193268 
Ferreira-Gonzalez, I. (2014). The Epidemiology of Coronary Heart Disease. Revista 
Espanola De Cardiologia, 67(2), 139-144. doi: 10.1016/j.rec.2013.10.002 
Foley, D., Ancoli-Israel, S., Britz, P., & Walsh, J. (2004). Sleep disturbances and chronic 
disease in older adults - Results of the 2003 National Sleep Foundation Sleep in 
America Survey. Journal of Psychosomatic Research, 56(5), 497-502. doi: 
10.1016/j.jpsychores.2004.02.010 
Freiberg, M. S., Chang, C. C., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. 
L., . . . Justice, A. C. (2013). HIV infection and the risk of acute myocardial 
infarction. Journal of the American Medical Association, 173(8), 614-622. doi: 
10.1001/jamainternmed.2013.3728 
 
 
60 
 
  27 
Fultz, S. L., Skanderson, M., Mole, L. A., Gandhi, N., Bryant, K., Crystal, S., & Justice, 
A. C. (2006). Development and verification of a "virtual" cohort using the 
National VA Health Information System. Medical Care, 44(8 Suppl 2), S25-30. 
doi: 10.1097/01.mlr.0000223670.00890.74 
Gamaldo, C. E., Spira, A. P., Hock, R. S., Salas, R. E., McArthur, J. C., David, P. M., . . . 
Smith, M. T. (2013). Sleep, Function and HIV: A Multi-Method Assessment. Aids 
and Behavior, 17(8), 2808-2815. doi: 10.1007/s10461-012-0401-0 
Gay, C. L., Zak, R. S., Lerdal, A., Pullinger, C. R., Aouizerat, B. E., & Lee, K. A. (2015). 
Cytokine polymorphisms and plasma levels are associated with sleep onset 
insomnia in adults living with HIV/AIDS. Brain Behavior and Immunity, 47, 58-
65. doi: 10.1016/j.bbi.2014.11.018 
Gill, J., May, M., Lewden, C., Saag, M., Mugavero, M., Reiss, P., . . . Antiretroviral 
Therapy Cohort, C. (2010). Causes of Death in HIV-1-Infected Patients Treated 
with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV 
Cohort Studies. Clinical Infectious Diseases, 50(10), 1387-1396. doi: 
10.1086/652283 
Haario, P., Rahkonen, O., Laaksonen, M., Lahelma, E., & Lallukka, T. (2013). 
Bidirectional associations between insomnia symptoms and unhealthy behaviours. 
Journal of Sleep Research, 22(1), 89-95. doi: 10.1111/j.1365-2869.2012.01043.x 
Hoefelmann, L. P., Lopes, A. D., da Silva, K. S., da Silva, S. G., Cabral, L. G. A., & 
Nahas, M. V. (2012). Lifestyle, self-reported morbidities, and poor sleep quality 
among Brazilian workers. Sleep Medicine, 13(9), 1198-1201. doi: 
10.1016/j.sleep.2012.05.009 
61 
 
  27 
Holliday, E. G., Magee, C. A., Kritharides, L., Banks, E., & Attia, J. (2013). Short Sleep 
Duration Is Associated with Risk of Future Diabetes but Not Cardiovascular 
Disease: a Prospective Study and Meta-Analysis. Plos One, 8(11), 8. doi: 
10.1371/journal.pone.0082305 
Horton, N. J., & Kleinman, K. P. (2007). Much ado about nothing: A comparison of 
missing data methods and software to fit incomplete data regression models. The 
American Statistician, 61(1), 79-90. doi: 10.1198/000313007x172556 
Hsu, C. Y., Chen, Y. T., Chen, M. F., Huang, C. C., Chiang, C. H., Huang, P. H., . . . 
Chan, W. L. (2015). The association between insomnia and increased future 
cardoiovascular events: A nationwide population-based study. Psychosomatic 
Medicine, 77(7), 743-751. doi: 10.1097/psy.0000000000000199 
Htoo, A., Talwar, A., Feinsilver, S. H., & Greenberg, H. (2004). Smoking and sleep 
disorders. Medical Clinics of North America, 88(6), 1575-+. doi: 
10.1016/j.mcna.2004.07.003 
Irwin, M. R., Olmstead, R., & Carroll, J. E. (2015). Sleep Disturbance, Sleep Duration, 
And Inflammation: A Systematic Review And Meta-Analysis Of Cohort Studies 
And Experimental Sleep Deprivation. Biological Psychiatry, 1(80), 40-52. doi: 
http://dx.doi.org/10.1016/j.biopsych.2015.05.014 
Islam, F. M., Wu, J., Jansson, J., & Wilson, D. P. (2012). Relative risk of cardiovascular 
disease among people living with HIV: a systematic review and meta-analysis. 
HIV Medicine, 13(8), 453-468. doi: 10.1111/j.1468-1293.2012.00996.x 
 
 
62 
 
  27 
Ives, D. G., Fitzpatrick, A. L., Bild, D. E., Psaty, B. M., Kuller, L. H., Crowley, P. 
M., . . . Theroux, S. (1995). Surveillance and ascertainment of cardiovascular 
events: The Cardiovascular Health Study. Annals of Epidemiology, 5(4), 278-285. 
doi: 10.1016/1047-2797(94)00093-9 
Jabbari, F., Dabaghzadeh, F., Khalili, H., & Abbasian, L. (2015). Associated factors of 
sleep quality in HIV-positive individuals. Future Virology, 10(2), 89-96. doi: 
10.2217/fvl.14.107 
Jackowska, M., & Steptoe, A. (2015). Sleep and future cardiovascular risk: prospective 
analysis from the English Longitudinal Study of Ageing. Sleep Medicine, 16(6), 
768-774. doi: 10.1016/j.sleep.2015.02.530 
Janson, C., Lindberg, E., Gislason, T., Elmasry, A., & Boman, G. (2001). Insomnia in 
men - A 10-year prospective population based study. Sleep, 24(4), 425-430.  
Jansson-Frojmark, M., & Linton, S. J. (2008). The course of insomnia over one year: a 
longitudinal study in the general population in Sweden. Sleep, 31(6), 881-886.  
Jaussent, I., Dauvilliers, Y., Ancelin, M.-L., Dartigues, J.-F., Tavernier, B., Touchon, 
J., . . . Besset, A. (2011). Insomnia Symptoms in Older Adults: Associated Factors 
and Gender Differences. The American Journal of Geriatric Psychiatry, 19(1), 
88-97. doi: https://doi.org/10.1097/JGP.0b013e3181e049b6 
Jean-Louis, G., Weber, K. M., Aouizerat, B. E., Levine, A. M., Maki, P. M., Liu, C. 
L., . . . Wilson, T. E. (2012). Insomnia Symptoms and HIV Infection among 
Participants in the Women's Interagency HIV Study. Sleep, 35(1), 131-137. doi: 
10.5665/sleep.1602 
63 
 
  27 
Justice, A. C., Dombrowski, E., Conigliaro, J., Fultz, S. L., Gibson, D., Madenwald, 
T., . . . Bryant, K. (2006). Veterans Aging Cohort Study (VACS): Overview and 
description. Medical Care, 44(8 Suppl 2), S13-24. doi: 
10.1097/01.mlr.0000223741.02074.66 
Justice, A. C., Holmes, W., Gifford, A. L., Rabeneck, L., Zackin, R., Sinclair, G., . . . 
Wu, A. W. (2001). Development and validation of a self-completed HIV 
symptom index. Journal of Clinical Epidemiology, 54 Suppl 1, S77-90.  
Kalmbach, D. A., Pillai, V., Arnedt, J. T., & Drake, C. L. (2016). DSM-5 Insomnia and 
Short Sleep: Comorbidity Landscape and Racial Disparities. Sleep, 39(12), 2101-
2111. doi: 10.5665/sleep.6306 
Klein, D., Hurley, L. B., Quesenberry, C. P., & Sidney, S. (2002). Do protease inhibitors 
increase the risk for coronary heart disease in patients with HIV-1 infection? 
Journal of Acquired Immune Deficiency Syndromes, 30(5), 471-477. doi: 
10.1097/01.qai.0000021391.89256.97 
Kohansieh, M., & Makaryus, A. N. (2015). Sleep Deficiency and Deprivation Leading to 
Cardiovascular Disease. International Journal of Hypertension, 5. doi: 
10.1155/2015/615681 
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: validity of a brief 
depression severity measure. Journal of General Internal Medicine, 16(9), 606-
613.  
 
 
64 
 
  27 
Lang, S., Boccara, F., Mary-Krause, M., & Cohen, A. (2015). Epidemiology of coronary 
heart disease in HIV-infected versus uninfected individuals in developed 
countries. Archives of Cardiovascular Diseases, 108(3), 206-215. doi: 
10.1016/j.acvd.2015.01.004 
Lang, S., Mary-Krause, M., Simon, A., Partisani, M., Gilquin, J., Cotte, L., . . . French 
Hosp Database, H. F.-A. (2012). HIV Replication and Immune Status Are 
Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected 
Individuals. Clinical Infectious Diseases, 55(4), 600-607. doi: 10.1093/cid/cis489 
LeBlanc, M., Merette, C., Savard, J., Ivers, H., Baillargeon, L., & Morin, C. M. (2009). 
Incidence and risk factors of insomnia in a population-based sample. Sleep, 32(8), 
1027-1037.  
Lee, K. A., Gay, C., Pullinger, C. R., Hennessy, M. D., Zak, R. S., & Aouizerat, B. E. 
(2014). Cytokine polymorphisms are associated with poor sleep maintenance in 
adults living with human immunodeficiency virus/acquired immunodeficiency 
syndrome. Sleep, 37(3), 453-463. doi: 10.5665/sleep.3474 
Leger, D., Guilleminault, C., Dreyfus, J. P., Delahaye, C., & Paillard, M. (2000). 
Prevalence of insomnia in a survey of 12 778 adults in France. Journal of Sleep 
Research, 9(1), 35-42. doi: 10.1046/j.1365-2869.2000.00178.x 
Levenson, J. C., Kay, D. B., & Buysse, D. J. (2015). THe pathophysiology of insomnia. 
Chest, 147(4), 1179-1192. doi: 10.1378/chest.14-1617 
 
 
65 
 
  27 
Li, M., Zhang, X.-W., Hou, W.-S., & Tang, Z.-Y. (2014). Insomnia and risk of 
cardiovascular disease: A meta-analysis of cohort studies. International Journal 
of Cardiology, 176(3), 1044-1047. doi: 
http://dx.doi.org/10.1016/j.ijcard.2014.07.284 
Libby, P. (2003). Vascular biology of atherosclerolsis: Overview and state of the art. 
American Journal of Cardiology, 91(3), 3A-6A.  
Libby, P. (2006). Inflammation and cardiovascular disease mechanisms. American 
Journal of Clinical Nutrition, 83(2), 456S-460S.  
Longenecker, C. T., Sullivan, C., & Baker, J. V. (2016). Immune activation and 
cardiovascular disease in chronic HIV infection. Current Opinion in HIV and 
AIDs, 11(2), 216-225. doi: 10.1097/coh.0000000000000227 
Low, Y., Goforth, H., Preud'homme, X., Edinger, J., & Krystal, A. (2014). Insomnia in 
HIV-infected patients: pathophysiologic implications. AIDS Reviews, 16(1), 3-13.  
Lucas, S., & Nelson, A. M. (2015). HIV and the spectrum of human disease. Journal of 
Pathology, 235(2), 229-241. doi: 10.1002/path.4449 
Lyytikainen, P., Lallukka, T., Lahelma, E., & Rahkonen, O. (2011). Sleep problems and 
major weight gain: a follow-up study. International Journal of Obesity, 35(1), 
109-114. doi: 10.1038/ijo.2010.113 
Manea, L., Gilbody, S., & McMillan, D. (2012). Optimal cut-off score for diagnosing 
depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. 
CMAJ : Canadian Medical Association Journal, 184(3), E191-E196. doi: 
10.1503/cmaj.110829 
66 
 
  27 
Michal, M., Wiltink, J., Kirschner, Y., Schneider, A., Wild, P. S., Munzel, T., . . . Beutel, 
M. E. (2014). Complaints of Sleep Disturbances Are Associated with 
Cardiovascular Disease: Results from the Gutenberg Health Study. Plos One, 
9(8). doi: 10.1371/journal.pone.0104324 
Morin, & Jarrin, D. C. (2013). Epidemiology of Insomnia: Prevalence, Course, Risk 
Factors, and Public Health Burden. Sleep Medicine Clinics, 8(3), 281-297. doi: 
http://dx.doi.org/10.1016/j.jsmc.2013.05.002 
Morin, LeBlanc, M., Bélanger, L., Ivers, H., & Mérette, C. (2011). Epidemiology of 
insomnia in the adult Canadian population. The Canadian Journal of Psychiatry, 
56, 540-548.  
Morin, LeBlanc, M., Daley, M., Gregoire, J. P., & Merette, C. (2006). Epidemiology of 
insomnia: prevalence, self-help treatments, consultations, and determinants of 
help-seeking behaviors. Sleep Medicine, 7(2), 123-130. doi: 
10.1016/j.sleep.2005.08.008 
Morin, C. M., Belleville, G., Belanger, L., & Ivers, H. (2011). The Insomnia Severity 
Index: Psychometric indicators to detect insomnia cases and evaluate treatment 
response. Sleep, 34(5), 601-608.  
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010). The Science of Stroke: Mechanisms 
in Search of Treatments. Neuron, 67(2), 181-198. doi: 
10.1016/j.neuron.2010.07.002 
 
 
67 
 
  27 
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, 
M., . . . Turner, M. B. (2015). Heart Disease and Stroke Statistics—2015 Update: 
A Report From the American Heart Association. Circulation, 131(4), e29-e322. 
doi: 10.1161/cir.0000000000000152 
Ohayon, M. M. (2002). Epidemiology of insomnia: what we know and what we still need 
to learn. Sleep Medicine Reviews, 6(2), 97-111.  
Ohayon, M. M., & Reynolds, C. F., 3rd. (2009). Epidemiological and clinical relevance 
of insomnia diagnosis algorithms according to the DSM-IV and the International 
Classification of Sleep Disorders (ICSD). Sleep Medicine, 10(9), 952-960. doi: 
10.1016/j.sleep.2009.07.008 
Paisible, A. L., Chang, C. C., So-Armah, K. A., Butt, A. A., Leaf, D. A., Budoff, M., . . . 
Freiberg, M. S. (2015). HIV Infection, Cardiovascular Disease Risk Factor 
Profile, and Risk for Acute Myocardial Infarction. Journal of Acquired Immune 
Deficiciney Syndromes, 68(2), 209-216. doi: 10.1097/qai.0000000000000419 
Palagini, L., Biber, K., & Riemann, D. (2014). The genetics of insomnia - Evidence for 
epigenetic mechanisms? Sleep Medicine Reviews, 18(3), 225-235. doi: 
10.1016/j.smrv.2013.05.002 
Patel, P., Borkowf, C. B., Brooks, J. T., Lasry, A., Lansky, A., & Mermin, J. (2014). 
Estimating per-act HIV transmission risk: a systematic review. AIDs, 28(10), 
1509-1519. doi: 10.1097/qad.0000000000000298 
 
 
68 
 
  27 
Peduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995). Importance of events 
per independent variable in proportional hazards regression analysis II. Accuracy 
and precision of regression estimates. Journal of Clinical Epidemiology, 48(12), 
1503-1510. doi: http://dx.doi.org/10.1016/0895-4356(95)00048-8 
Reid, S., & Dwyer, J. (2005). Insomnia in HIV infection: A systematic review of 
prevalence, correlates, and management. Psychosomatic Medicine, 67(2), 260-
269. doi: 10.1097/01.psy.0000151771.46127.df 
Riley, R. F., Don, C. W., Powell, W., Maynard, C., & Dean, L. S. (2011). Trends in 
Coronary Revascularization in the United States From 2001 to 2009: Recent 
Declines in Percutaneous Coronary Intervention Volumes. Circulation. 
Cardiovascular Quality and Outcomes, 4(2), 193-197. doi: 
10.1161/CIRCOUTCOMES.110.958744 
Rod, N. H., Kumari, M., Lange, T., Kivimaki, M., Shipley, M., & Ferrie, J. (2014). The 
Joint Effect of Sleep Duration and Disturbed Sleep on Cause-Specific Mortality: 
Results from the Whitehall II Cohort Study. Plos One, 9(4), 10. doi: 
10.1371/journal.pone.0091965 
Roth, T., Jaeger, S., Jin, R., Kalsekar, A., Stang, P. E., & Kessler, R. C. (2006). Sleep 
problems, comorbid mental disorders, and role functioning in the national 
comorbidity survey replication. Biological Psychiatry, 60(12), 1364-1371.  
Rubinstein, M. L., & Selwyn, P. A. (1998). High prevalence of insomnia in an outpatient 
population with HIV infection. Journal of Acquired Immune Deficiency 
Syndromes and Human Retrovirology, 19(3), 260-265.  
69 
 
  27 
Ruiter, M. E., DeCoster, J., Jacobs, L., & Lichstein, K. L. (2010). Sleep Disorders in 
African Americans and Caucasian Americans: A Meta-Analysis. Behavioral 
Sleep Medicine, 8(4), 246-259. doi: 10.1080/15402002.2010.509251 
Ruiter, M. E., DeCoster, J., Jacobs, L., & Lichstein, K. L. (2011). Normal sleep in 
African-Americans and Caucasian-Americans: A meta-analysis. Sleep Medicine, 
12(3), 209-214. doi: https://doi.org/10.1016/j.sleep.2010.12.010 
Sands-Lincoln, M., Loucks, E. B., Lu, B., Carskadon, M. A., Sharkey, K., Stefanick, M. 
L., . . . Eaton, C. B. (2013). Sleep Duration, Insomnia, and Coronary Heart 
Disease Among Postmenopausal Women in the Women's Health Initiative. 
Journal of Womens Health, 22(6), 477-486. doi: 10.1089/jwh.2012.3918 
Schramm, E., Hohagen, F., Grasshoff, U., Riemann, D., Hajak, G., Weess, H. G., & 
Berger, M. (1993). Test-retest reliability and validity of the Structured Interview 
for Sleep Disorders According to DSM-III-R. American Journal of Psychiatry, 
150(6), 867-872. doi: 10.1176/ajp.150.6.867 
Schwartz, S., Anderson, W. M., Cole, S. R., Cornoni-Huntley, J., Hays, J. C., & Blazer, 
D. (1999). Insomnia and heart disease: A review of epidemiologic studies. 
Journal of Psychosomatic Research, 47(4), 313-333.  
Silverberg, M. J., Leyden, W. A., Xu, L. F., Horberg, M. A., Chao, C. R., Towner, W. 
J., . . . Klein, D. B. (2014). Immunodeficiency and Risk of Myocardial Infarction 
Among HIV-Positive Individuals With Access to Care. Journal of Acquired 
Immune Deficiency Syndromes, 65(2), 160-166. doi: 
10.1097/qai.0000000000000009 
70 
 
  27 
Sivertsen, B., Krokstad, S., Øverland, S., & Mykletun, A. (2009). The epidemiology of 
insomnia: Associations with physical and mental health.: The HUNT-2 study. 
Journal of Psychosomatic Research, 67(2), 109-116. doi: 
https://doi.org/10.1016/j.jpsychores.2009.05.001 
Sofi, F., Cesari, F., Casini, A., Macchi, C., Abbate, R., & Gensini, G. F. (2014). Insomnia 
and risk of cardiovascular disease: a meta-analysis. European Journal of 
Preventive Cardiology, 21(1), 57-64. doi: 10.1177/2047487312460020 
Spielman, A. J., Caruso, L. S., & Glovinsky, P. B. (1987). A BEHAVIORAL-
PERSPECTIVE ON INSOMNIA TREATMENT. Psychiatric Clinics of North 
America, 10(4), 541-553.  
Stamatakis, K. A., Kaplan, G. A., & Roberts, R. E. (2007). Short Sleep Duration Across 
Income, Education, and Race/Ethnic Groups: Population Prevalence and Growing 
Disparities During 34 Years of Follow-Up. Annals of Epidemiology, 17(12), 948-
955. doi: https://doi.org/10.1016/j.annepidem.2007.07.096 
Stepanski, E. J., & Wyatt, J. K. (2003). Use of sleep hygiene in the treatment of 
insomnia. Sleep Medicine Reviews, 7(3), 215-225. doi: 10.1053/smrv.2001.0246 
Sullivan, P. S., Jones, J. S., & Baral, S. D. (2014). The global north: HIV epidemiology in 
high-income countries. Current Opinion in HIV and AIDs, 9(2), 199-205. doi: 
10.1097/coh.0000000000000039 
Taylor, D. J., Mallory, L. J., Lichstein, K. L., Durrence, H. H., Riedel, B. W., & Bush, A. 
J. (2007). Comorbidity of chronic insomnia with medical problems. Sleep, 30(2), 
213-218.  
71 
 
  27 
Terzano, M. G., Parrino, L., Cirignotta, F., Ferini-Strambi, L., Gigli, G., Rudelli, G., . . . 
Studio Morfeo, C. (2004). Studio Morfeo: insomnia in primary care, a survey 
conducted on the Italian population. Sleep Medicine, 5(1), 67-75. doi: 
10.1016/j.sleep.2003.09.006 
Thygesen, K., Alpert, J. S., Jaffe, A. S., White, H. D., Simoons, M. L., Chaitman, B. 
R., . . . Mendis, S. (2012). Third Universal Definition of Myocardial Infarction. 
Journal of the American College of Cardiology, 60(16), 1581-1598. doi: 
10.1016/j.jacc.2012.08.001 
Thygesen, K., Alpert, J. S., White, H. D., Infarction, o. b. o. t. J. E. A. A. W. T. F. f. t. R. 
o. M., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen , J. S. A., 
Harvey D. White, Biomarker Group: Allan S. Jaffe, C., Fred S. Apple , Marcello 
Galvani , Hugo A. Katus , L. Kristin Newby , Jan Ravkilde, . . . Joao Morais, R. 
C., Sorin Brener , Robert Harrington , David Morrow , Udo Sechtem , Michael 
Lim , Marco A. Martinez-Rios , Steve Steinhubl , Glen N. Levine , W. Brian 
Gibler , David Goff , Marco Tubaro , Darek Dudek , Nawwar Al-Attar. (2007). 
Universal Definition of Myocardial Infarction. Circulation, 116(22), 2634-2653. 
doi: 10.1161/circulationaha.107.187397 
Tractenberg, R. E., Singer, C. M., & Kaye, J. A. (2005). Symptoms of sleep disturbance 
in persons with Alzheimer's disease and normal elderly. Journal of Sleep 
Research, 14(2), 177-185. doi: 10.1111/j.1365-2869.2005.00445.x 
 
 
72 
 
  27 
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007). Increased acute 
myocardial infarction rates and cardiovascular risk factors among patients with 
human immunodeficiency virus disease. Journal of Clinical Endocrinology & 
Metabolism, 92(7), 2506-2512. doi: 10.1210/jc.2006-2190 
Tseng, A., Seet, J., & Phillips, E. J. (2015). The evolution of three decades of 
antiretroviral therapy: challenges, triumphs and the promise of the future. British 
Journal of Clinical Pharmacology, 79(2), 182-194. doi: 10.1111/bcp.12403 
UNAIDS. (2013). Global report 2013: UNAIDS report on the global AIDS epidemic 
2013. from 
http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/document
s/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf 
Vgontzas, A. N., Bixler, E. O., Lin, H. M., Prolo, P., Mastorakos, G., Vela-Bueno, A., . . . 
Chrousos, G. P. (2001). Chronic insomnia is associated with nyctohemeral 
activation of the hypothalamic-pituitary-adrenal axis: Clinical implications. 
Journal of Clinical Endocrinology & Metabolism, 86(8), 3787-3794. doi: 
10.1210/jc.86.8.3787 
Vgontzas, A. N., Calhoun, S., Liao, D. P., Karataraki, M., Pejovic, S., & Bixler, E. O. 
(2009). Insomnia with Objective Short Sleep Duration Is Associated With Type 2 
Diabetes A population-based study. Diabetes Care, 32(11), 1980-1985. doi: 
10.2337/dc09-0284 
Vgontzas, A. N., Liao, D. P., Bixler, E. O., Chrousos, G. P., & Vela-Bueno, A. (2009). 
Insomnia with Objective Short Sleep Duration is Associated with a High Risk for 
Hypertension. Sleep, 32(4), 491-497.  
73 
 
  27 
Vos, A. G., Idris, N. S., Barth, R. E., Klipstein-Grobusch, K., & Grobbee, D. E. (2016). 
Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV 
Infection. A Systematic Review. Plos One, 11(1), e0147484. doi: 
10.1371/journal.pone.0147484 
Weber, C., & Noels, H. (2011). Atherosclerosis: current pathogenesis and therapeutic 
options. Nature Medicine, 17(11), 1410-1422. doi: 10.1038/nm.2538 
Westerlund, A., Bellocco, R., Sundstrom, J., Adami, H. O., Akerstedt, T., & Lagerros, Y. 
T. (2013). Sleep characteristics and cardiovascular events in a large Swedish 
cohort. European Journal of Epidemiology, 28(6), 463-473. doi: 10.1007/s10654-
013-9802-2 
Wichniak, A., Wierzbicka, A., & Jernajczyk, W. (2012). Sleep and antidepressant 
treatment. Current Pharmaceutical Design, 18(36), 5802-5817.  
Wilt, T. J., MacDonald, R., Brasure, M., Olson, C. M., Carlyle, M., Fuchs, E., . . . Kane, 
R. L. (2016). Pharmacologic Treatment of Insomnia Disorder: An Evidence 
Report for a Clinical Practice Guideline by the American College of Physicians. 
Annals of Internal Medicine, 165(2), 103-112. doi: 10.7326/m15-1781 
Wirth, M. D., Jaggers, J. R., Dudgeon, W. D., Hebert, J. R., Youngstedt, S. D., Blair, S. 
N., & Hand, G. A. (2015). Association of Markers of Inflammation with Sleep 
and Physical Activity Among People Living with HIV or AIDS. AIDS and 
Behavior, 19(6), 1098-1107. doi: 10.1007/s10461-014-0949-y 
Wolkove, N., Elkholy, O., Baltzan, M., & Palayew, M. (2007). Sleep and aging: 1. Sleep 
disorders commonly found in older people. Canadian Medical Association 
Journal, 176(9), 1299-1304. doi: 10.1503/cmaj.060792 
74 
 
  27 
Womack, J. A., Murphy, T. E., Bathulapalli, H., Akgun, K. M., Gibert, C., Kunisaki, K. 
M., . . . Redeker, N. S. (2017). Sleep Disturbance Among HIV-Infected and 
Uninfected Veterans. Jaids-Journal of Acquired Immune Deficiency Syndromes, 
74(4), E117-E120.  
World Health Organization. (2015). Cardiovascvular diseases (CVDs). from 
http://www.who.int/mediacentre/factsheets/fs317/en/ 
Wu, J., Wu, H., Lu, C. Y., Guo, L., & Li, P. S. (2015). Self-reported sleep disturbances in 
HIV-infected people: a meta-analysis of prevalence and moderators. Sleep 
Medicine, 16(8), 901-907. doi: 10.1016/j.sleep.2015.03.027 
Zhang, B., & Wing, Y. K. (2006). Sex differences in insomnia: a meta-analysis. Sleep, 
29(1), 85-93. 
